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Abstract 
Research background and aims. The aim of this study was to establish and characterise iPSC-
lines generated with two different methods, as well as to differentiate the created cells into 
cardiomyocytes, maintaining a comparative view. Since traditional culture conditions include 
xenogenic and undefined components, also an experiment on establishing and maintaining 
iPSCs feeder-free was conducted. In addition to studying the reprogramming efficiency, also 
the expression of pluripotency genes was studied quantitatively at mRNA level. 
Materials and methods. iPSCs generated from patient fibroblasts were characterised by 
studying the expression of exogenous and endogenous pluripotency genes by PCR an RT-PCR, 
staining the cells with pluripotency markers, karyotyping and an embryoid body in vitro -
differentiation potential assay, and RT-PCR to detect markers for each germ layer. The 
cardiomyocyte differentiation was performed in co-culture with END-2 cells. Pluripotency 
gene expression was also studied with real-time qPCR at passages 3 and 9. 
Results. All studied iPSC-lines except one Geltrex®-line lost at p. 9 showed successful 
reprogramming with no qualitative differences between sendai-virally or episomally 
reprogrammed lines. The lines that were cultured feeder-free stained positive for neural 
markers, and differentiated, neural precursor-like cells were present at all passages, which was 
not encountered for MEF-cultured lines. For the two cardiac-differentiated lines, the efficiency 
of differentiation assessed in two ways showed a more efficient differentiation of the sendai-
virally reprogrammed line than the one reprogrammed with episomal plasmids. Gene 
expression studies showed no significant changes in pluripotency gene expression between 
lines or passages except for the gene NANOG, the expression of which was lower in the later 
passage than the earlier passage. The reprogramming efficiencies observed were extremely low, 
in the range of 0,005–0,017%. 
Conclusions. Although stem cell research is trying to generate feeder-free and xeno-free 
methods for iPSC generation and maintenance, the method tested in this thesis did not possess 
real advantages when compared to the MEF-culturing. The reprogramming efficiencies 
between feeder-free or MEF-cultured lines derived episomally did not differ. The pluripotency 
genes were already highly expressed in early passage iPSCs. The differences in pluripotency 
gene expression between early and late passages were small. Cardiac differentiation was more 
efficient for sendai-virally reprogrammed line compared to episomally differentiated line. 
However, more lines would be needed to verify these results.  
 
Key words induced pluripotent stem cell (iPSC), mouse embryonic feeder (MEF), 
cardiomyocyte, cardiac differentiation, reprogramming efficiency, differentiation efficiency, 
episomal plasmid 
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Tiivistelmä 
Tutkielman tausta ja tavoitteet. Tämän Pro Gradu -työn tarkoituksen oli luoda ja 
karakterisoida kahdella eri menetelmällä uusia indusoituja pluripotentteja kantasolulinjoja, 
sekä erilaistaa niitä sydänlihassoluiksi END-2-erilaistusmenetelmällä vertailevalla otteella. 
Koska perinteiset soluviljelymenetelmät sisältävät eläinperäisiä soluja sekä tuntemattomia 
tekijöitä, tutkittiin myös soluvapaan Geltrex®-matriisin ja mTeSR1- kasvatusmediumin 
soveltuvuutta indusoitujen kantasolujen luontiin ja ylläpitoon. Lisäksi tutkittiin 
uudelleenohjelmoinnin tehokkuutta sekä pluripotenssigeenien aktivoitumista 
uudelleenohjelmoinnin alkuvaiheessa. 
Tutkimusmenetelmät. Luotuja kantasolulinjoja kasvatettiin yhteisviljelmissä MEF-solujen 
kanssa ja linjat karakterisoitiin tutkimalla eksogeenisten ja endogeenisten pluripotenssigeenien 
ilmentymistä PCR:n, RT-PCR:n ja määrällisesti real-time qPCR:n avulla, sekä proteiinitasolla 
immunovärjäämällä pluripotenssiproteiineja. In vitro -erilaistumista tutkittiin embryoid body-
menetelmällä sekä tunnistamalla niistä RT-PCR:n avulla eri alkion kerrosten läsnäolo. 
Sydänerilaistus suoritettiin yhteisviljelmässä END-2 solujen kanssa.  
Tutkimustulokset. Kaikki tutkitut linjat yhtä Geltrex®:llä kasvatettua linjaa lukuun ottamatta 
todettiin uudelleenohjelmoituneiksi karakterisointien perusteella. Sendai-virusmenetelmällä 
luotu solulinja erilaistui tehokkaammin sydänlihassoluiksi kuin episomaalisilla plasmideilla 
uudelleenohjelmoitu solulinja. Soluvapaalla alustalla kasvatetut kantasolulinjat erilaistuivat 
spontaanisti MEF-yhteisviljelmissä kasvavia iPS-soluja enemmän, ja ilmensivät alkeellisille 
hermosoluille tyypillisiä proteiineja. Uudelleenohjelmoinnin tehokkuus kaikille linjoille oli 
matala, 0,005–0,017 %. Pluripotenssigeeniekspressiossa ei potilaiden tai eri aikapisteiden 
välillä havaittu merkittäviä muutoksia kuin yhdelle geenille, NANOG:lle, jonka ilmentyminen 
myöhemmässä vaiheessa oli alhaisempi kuin aikaisemmassa aikapisteessä. 
Johtopäätökset. Verrattaessa perinteistä viljelymenetelmää yhteisviljelmissä eläinperäisten 
MEF-solujen kanssa, tässä lopputyössä testatussa soluvapaassa menetelmässä ei saavutettu 
suuria etuja vaan niissä havaittiin suuria määriä erilaistuneita hermosolujen esiasteita. MEF-
yhteisviljelmissä sekä soluvapaalla Geltrex®-matriisilla uudelleenohjelmoitujen iPS-solujen 
erilaistumistehokkuudet eivät eronneet merkittävästi toisistaan. Pluripotenssigeenit 
aktivoituvat jo aikaisessa vaiheessa ja ilmentymistasojen vaihtelut olivat alhaisia. Sendai-
virusmenetelmällä luotu iPS-solulinja erilaistui tehokkaammin sydänlihassoluiksi kuin 
plasmideilla luotu iPS-linja. Koska tulokset koostuivat vain kahden linjan vertailusta, useampia 
linjoja tarvitaan tulosten varmistamiseksi. 
 
Avainsanat indusoitu pluripotentti kantasolu (iPS-solu), hiiren alkion fibroblasti (MEF), 
episomaalinen plasmidi, sydänlihassolu, sydänerilaistus, uudelleenohjelmointitehokkuus, 
erilaistustehokkuus 
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1.  Introduction 
The discovery of Yamanaka and Takahashi in 2006 that somatic adult cells could be 
reprogrammed back into a pluripotent state by introducing four distinct transcription factors 
(Takahashi and Yamanaka, 2006) changed the frame in which stem cell research is now 
conducted. They named these stem cells induced pluripotent stem cells (iPSCs). iPSCs are 
embryonic stem cell (ESC)-like cells that are able to differentiate into cells of all the three germ 
layers, i.e. into all cell types except the extra-embryonic tissues. Previously research had 
focused on studying the embryonic stem cells. Because of their limited availability (in Finland 
for example available only from non-implantable embryos derived for fertility treatments) and 
ethical considerations, the generation of iPSCs revolutionised the research. Now pluripotent 
stem cells from any individual and multiple cell types could be obtained. Since the emergence, 
the first steps included the generation of first human iPSCs (Takahashi et al., 2007; Yu et al., 
2007) and verification of the ESC-like pluripotent state. The iPSCs have indeed been 
established to be equivalent to ESCs morphologically, functionally, epigenetically and 
transcriptionally (Maherali et al., 2007; Mikkelsen et al., 2008; Okita, et al. 2007; Takahashi et 
al., 2007; Wernig et al., 2007). 
IPSCs have many uses. As such they can be used to study developmental biology, a subject that 
only little is known of since human embryonic development is challenging to study. As they 
can theoretically be differentiated into any cell type, in vitro -disease models for modelling of 
diseases can be made. These models can also be used for drug and toxicity screening, offering 
more insight to drug safety than is obtained with animal studies only. The iPS-research is now 
focused on finding the best generation methods, cell types, factors and culture conditions to 
obtain high-quality iPSCs (Brouwer et al., 2016).  
Cardiac differentiation methods have been generated already for human ES-cells and later 
adapted to differentiate iPS-cells. Ultimately, the differentiated cardiomyocytes could possibly 
be used in the repair and regeneration of cardiac tissue (Batalov and Feinberg, 2015). However, 
this goal is still far away. Currently, the differentiated cardiomyocytes can be used for disease 
modeling, drug testing and toxicity screening. Moreover, as patient-specific lines can be 
generated, lines from patients with various genetic cardiac disorders can and have been created 
(Terrenoire et al., 2013). The main research areas in the field are the development of more 
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effective in vitro -differentiation protocols, guidance of differentiation into special subtypes and 
methods to isolate them. Since cardiomyocyte obtained by differentiation of iPSCs express an 
immature, more fetal-like phenotype, the research is also focusing on generating 
cardiomyocytes of higher maturity. (Rajala et al., 2011) 
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2. Literature review 
2.1 Stem cells 
Stem cells are functionally undifferentiated cells possessing two key properties: they have the 
capacity to self-renew, and to differentiate into specialised cell types (Weissman et al., 2001; 
Smith, 2001). Self-renewal means that the cells can divide extensively, maybe even 
indefinitely, giving rise to identical undifferentiated daughter cells. In addition, these cells can 
also differentiate into at least one or multiple different cell types. During differentiation, the 
stem cell divides producing two daughter cells, of which the other differentiates and the other 
remains a stem cell. Two types of mechanisms for this are proposed: the first possibility is that 
the stem cell divides asymmetrically giving rise to two cells with a different complement of 
proteins. The other possibility is that the differentiation of the other daughter cell is caused by 
external signals: the daughter cell that does not differentiate occupies a specific stem cell niche 
and stays undifferentiated, while the other ends up outside the stem cell niche and differentiates. 
In many cases, both mechanisms may apply. (Wolpert et al., 2011) 
Stem cells can be classified according to their differentiation ability. During embryonic 
development in mammals, the fertilized egg possessed the ability to differentiate into all cell 
types in an individual, as well as extra-embryonic tissues, and is called totipotent. As the 
fertilized egg divides further, it forms the compacted morula, in which individual cell outlines 
are no longer visible. The insides of the morula form the inner cell mass seen at the later-stage 
blastocyst. The outer layer of the blastocyst gives rise to the trophectoderm, from which 
extraembryonic tissues placenta, umbilical cord and fetal membranes are later formed, while 
the inner cell mass gives rise to the embryo proper. All three germ layers - endoderm, mesoderm 
and ectoderm – are formed from the inner cell mass and they have the ability to differentiate 
into all cell types and tissues encountered in an individual. However, no extra-embryonic tissues 
can form from the inner cell mass, and the cells are referred to as pluripotent. (Wolpert et al., 
2011) 
As embryonic development gradually proceeds, the cells tend to lose their differentiation 
potential as they become more committed. Nonetheless, stem cells can still be found in various, 
but usually small, amounts in all adult tissues, where they are responsible for tissue renewal 
and repair (Wolpert et al., 2011). Depending on the tissue and stem cell, these adult stem cells 
can be either multipotent – capable of differentiating into more than one different cell types – 
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or unipotent, that can differentiate into a single cell type. For example, hematopoietic stem cells 
of the bone marrow are multipotent and can differentiate into all blood cells, whereas 
keratinocytes mature from unipotent stem cells in the deepest layer of the epidermis (Wolpert 
et al., 2011). Some debate has been going on as to whether the unipotent stem cells can be 
classified as stem cells, thus they are also often referred to as precursor cells (Melton, 2014). 
The different stem cell types are depicted in Figure 1. 
 
Figure 1. Classification of stem cells according to their differentiation ability. Totipotent stem 
cells of the fertilized egg can differentiate into all different cell types. Later on in the embryonic 
development, the inner cell mass of the blastocyst contains pluripotent stem cells able to 
differentiate into all other cell types except placental, umbilical cord- or extraembryonic 
membrane tissues. Pluripotent stem cells differentiate into cells of all three germ layers, which 
contain multipotent stem cell able to differentiate into multiple different cell types of a certain 
lineage, and ultimately form terminally differentiated cells that form the majority of adult 
tissues. (Menon et al., 2016) 
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The first embryonic stem (ES) cell lines were isolated from the inner cell mass of a mouse 
blastocyst, and were successfully maintained in in vitro -cultures (Evans and Kaufman, 1981; 
Martin, 1981). In the following years, many groups reported maintenance of undifferentiated, 
pluripotent embryonic stem cells from various origins in in vitro -cultures, and generation of 
differentiation protocols (Amit and Itskovitz-Eldor, 2002), that paved the way for the future 
discovery that revolutionised the stem cell research. Before it was thought that once the stem 
cell is committed into a specific lineage, it cannot differentiate into cells of another lineage. 
This thought has been compromised since and it has been shown that fully differentiated cells 
can transdifferentiate into another cell type, or not yet differentiated, but committed progenitor 
cells transdeterminate into another lineage (Wolpert et al., 2011). The most radical finding 
happened in 2006 when Takahashi and Yamanaka proved that fully differentiated cells could 
be reprogrammed back to the pluripotent state, introducing the concept of induced pluripotent 
stem (iPS) cells for the first time (Takahashi and Yamanaka, 2006). 
2.2 Induced pluripotent stem cells 
iPS-cells are pluripotent stem cells that can be produced from terminally differentiated cells, 
also from adult somatic cell by reprogramming. By introducing certain reprogramming factors 
into the cells, the cells dedifferentiate into a pluripotent, embryonic stem cell (ESC)-like state. 
(Takahashi and Yamanaka, 2006) Yamanaka and colleagues were able to produce mouse iPS-
cells from mouse skin fibroblast by retroviral transduction of four transcription factor genes 
found to be upregulated in ESCs coding for octamer-binding factor (Oct4), sex determining 
region Y-box 2 (Sox2), myelocytomatosis viral oncogene homolog (c-Myc) and Kruppel-like 
factor 4 (Klf4), called the Yamanaka-factors or OSKM. From the resulting cells, they were able 
to isolate and expand the reprogrammed iPS-cells. A year later the generation of human iPS-
cells was reported for the first time (Takahashi et al., 2007; Yu et al., 2007). 
Because of their potential to be differentiated theoretically into almost any cell type, iPS-cells 
have many possible applications including drug and toxicity screening, disease modeling, cell 
transplantation therapies and regenerative medicine. Moreover, the use of iPS-cells circumvents 
ethical issues related with ES-cell (Gonzalez et al., 2011; Seki and Fukuda, 2015). The use of 
autologous iPS-cells for cell therapies was thought to overcome problems regarding immune 
reactions caused by allogenic ES-cells, but has been compromised since 2011 when Zhao et al. 
reported immune responses in mice receiving syngeneic iPS-transplants (Zhao et al., 2011). 
This is thought to be contributed by genetic and epigenetic changes that occur randomly during 
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reprogramming (Doi et al., 2009; Kim et al., 2010; Polo et al., 2010), as well as by the 
immaturity of in vitro –differentiated cells and possibly xenogeneic or non-physiological 
components used in iPS-culture (Martin et al., 2005; Tang and Drukker, 2011). More recent 
studies have also reported negligible or no immune responses when using iPSCs produced with 
an integration-free method (Guha et al., 2013; Lu et al., 2014).  
Ever since the emergence of iPS-cells they have been studied extensively. The major problems 
concern low reprogramming efficiency, tumorigenic potential and genomic instability. The 
transcription factors Oct4 and Klf4 are known oncogenes, raising safety issues especially with 
clinical use. Viral reprogramming methods can cause genomic integration resulting in 
insertional mutagenesis, or result in incomplete silencing of the transgenes. The research has 
mainly been focusing on improving the iPS-technology by finding the most suitable cell 
sources, factors and methods for reprogramming, as well as development of optimal culture 
conditions to maintain the pluripotency of the generated iPS-cells. (Brouwer et al., 2016) 
2.2.1 Cell types for reprogramming 
Before reprogramming, a suitable cell type must be chosen. The cells should be easily obtained 
and susceptible to reprogramming, and preferably storable by freezing (Brouwer et al., 2016). 
Since reprogramming efficiencies are generally low, the cell source must be easily expandable 
to obtain enough cells for reprogramming. However, obtaining fibroblasts which are the cell 
type most often used for reprogramming, is an invasive procedure. More easily obtainable cells, 
such as cells from urine samples or cord blood cells have also been reprogrammed. Another 
advantage regarding the use of cord blood cells is that as immature cells they probably contain 
less somatic mutations and can be epigenetically easier to reprogram than adult cells, and could 
be stored in blood banks for later use. (Brouwer et al., 2016)  
The first reprogramming was performed with fibroblasts using the Yamanaka-factors 
(Takahashi and Yamanaka 2006), but the type of the somatic cell used also affects the 
transcription factors needed for successful reprogramming. For example, neural progenitor cells 
or melanocytes having high endogenous expression of SOX2 can be reprogrammed without 
SOX2 or even with OCT4 alone (Eminli et al. 2008; Kim et al 2008; Utikal et al., 2009a). The 
use of less reprogramming factors, however, usually also has an effect on reprogramming 
efficiency (Lai et al., 2011). 
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It has been shown that even after reprogramming, the iPSCs elicit an epigenetic memory of the 
original donor cell characterised by gene expression patterns and DNA methylation (Kim et al., 
2011; Bar-Nur et al., 2011; Marchetto et al., 2009; Ohi et al., 2011). Because of this, upon 
differentiation the iPSCs tend to differentiate more easily into cells of the same germ layer as 
the original donor cell (Kim et al., 2011; Bar-Nur et al., 2011). Thus, choosing a cell type from 
the same germ layer as the generated iPSCs will be differentiated to, can help to improve 
differentiation efficiency (Brouwer et al., 2016). As also demonstrated by Ohi et al., the 
silencing of donor cell type genes can be insufficient for many genes upon reprogramming (Ohi 
et al., 2011). As for improving differentiation efficiency, also the quality of the iPSCs will be 
improved by choosing a donor cell type of close origin to the one it will be differentiated to 
(Brouwer et al., 2016).  
The epigenetic profile in the created iPSCs is an important characteristic separating iPSCs and 
ESCs. In an example study by Hiler et al. iPSCs generated from rod photoreceptor cells 
differentiated more efficiently into the retinae than did ESCs (Hiler et al., 2015). On the other 
hand, differentiating cells into cells of another germ layer than the original cell types probably 
results in efficiencies lower than with the use of ESCs. However, the epigenetic, gene 
expression and differentiation potential differences between iPSCs and ESCs seem to be 
diminished during passaging of the iPSCs (Chin et al., 2009; Polo et al., 2010; Nishino et al., 
2011). As a result, the iPSCs are thought to lose the characteristics of the paternal cell type over 
time (Brouwer et al., 2016). So far most cell types used for reprogramming have been from a 
mesodermal origin, such as fibroblasts, adipose stem cells, dental pulp cells, cells from the 
hematopoietic lineage and urinary cells. Although more rarely, also cells form endodermal and 
ectodermal origins such as keratinocytes, hepatocytes, melanocytes and neural progenitor cells 
have been reprogrammed successfully. (Brouwer et al., 2016) 
2.2.2 Reprogramming factors  
Currently, there are many existing factors (or combination of factors) that can be used for 
reprogramming. Many of the factors inducing reprogramming are factors that are normally 
expressed in early embryos and are important for the maintenance of pluripotency in the embryo 
(Gonzalez et al., 2011). The original reprogramming cocktail used by Takahashi and Yamanaka 
in 2006 consisted of four transcription factors OCT3/4, SOX2, KLF4, and C-MYC, all factors 
found to be upregulated in ESCs (Takahashi and Yamanaka 2006; Takahashi et al., 2007). The 
efficiency of reprogramming occurred at an efficiency of 0,02% with adult human dermal 
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fibroblasts. These Yamanaka-factors are also the most common factors used for reprogramming 
(Seki and Fukuda, 2015). A bit later, another research group was reprogramming cells using a 
combination of transgenes SOX2, OCT4, NANOG and LIN28 (Yu et al., 2007).  
Since C-MYC is a known oncogene in humans, alternative methods omitting it from the 
Yamanaka-factor-cocktail also managed to achieve successful reprogramming, although with a 
much lower efficiency (Nakagawa et al., 2008; Wernig et al., 2008). On the other hand, adding 
proliferation-inducing human Telomerase reverse transcriptase (hTERT) and SV 40 large T 
antigen to the reprogramming cocktail an efficiency of up to 0,25% could be achieved with 
adult fibroblasts (Park et al., 2008). Adding UTF1 or SALL4, both transcription factors 
associated with pluripotency, with the Yamanaka-factors also resulted in more colonies than 
with the Yamanaka-factors alone (Gonzalez et al., 2011). As already described earlier, the cell 
type used for reprogramming also affects which factors need to be used.  
In addition to the actual reprogramming factors, also various facilitating compounds enhancing 
the efficiency of reprogramming can be added. For example, inhibition of the cell-cycle 
regulator mitogen-activated kinase kinase (MEK) results in enhanced reprogramming. 
Inhibition of reprogramming barriers such as cell senescence or apoptosis can also enhance 
reprogramming. Inhibition by short hairpin RNAs or knockout alleles of p53 or members of the 
same pathway resulted in increases in both speed and efficiency of reprogramming when 
compared to the use of Yamanaka-transcription factors alone. (Gonzalez et al., 2011) Other 
non-coding RNAs usually targeting the transforming growth factor beta (TGFβ) -pathway can 
be used to enhance reprogramming. A combination of microRNAs has also been used to 
achieve successful reprogramming without the use of transcription factors at a higher 
efficiency. (Anokye-Danso et al., 2011) 
The use of small molecules to enhance the rate-limiting step of chromatin remodeling has been 
shown to increase efficiency. The most used small molecules in reprogramming protocols are 
histone deacetylase inhibitors valproic acid and sodium butyrate. (Malik and Rao, 2013) 
Recently, reprogramming of mouse cells using only small molecules was achieved (Hou et al., 
2013). However, the results have not yet been demonstrated using human cells. The advantage 
using small molecules is that they don’t require any specific delivery method to enter the cell 
and can be administered at very specific amounts, making the process easier. However, the non-
specific effects can cause cellular toxicity. (Brouwer et al., 2016) 
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2.2.3 Culture conditions 
The culture conditions used for iPSC-reprogramming and maintenance are based on hESC-
culture conditions developed over the past decade (Chen et al., 2011). The iPSCs can be 
cultured either in colonies, non-colony monolayers or as suspension cultures. The most 
commonly used method is a colony-based feeder cell culture usually by co-culture with mouse 
embryonic fibroblast (MEF) feeder cells. The supportive cells secrete growth factors necessary 
for survival and maintenance as well as proliferation of human pluripotent stem cells. 
Traditional media are based on fetal calf or bovine serum replacement supplemented with β-
fibroblast growth factor (FGF). However, these traditional methods contain xenogenic cells 
and/or compounds, batch-to-batch variation in the biological media compounds and the fact 
that the factors secreted by the feeder cells remain unknown, poses safety issues. Especially for 
clinical use the iPSCs need to be cultured in fully defined, xeno-free conditions. (Brouwer et 
al., 2016) As a result, research has been focusing on the development on novel cell-free or 
totally xeno-free matrices and xeno-free media (Seki and Fukuda, 2015). 
While human feeder cells avoid the problem of xenobiotics, the high cost and difficulties in 
upscaling the production has let researchers to explore other options. Matrigel is probably one 
of the most used cell-free matrices used to generate and maintain iPSCs in non-colony type 
monolayer cultures. It also has the ability to increase cell viability and proliferation when 
compared to traditional colony-based culture with feeder cells. (Chen et al., 2012) Geltrex® is 
another cell-free matrix used for culture of iPSCs (Wagner and Welch, 2010) and both are 
derived from the murine Engelbreth-Holm-Swarm tumor. Also totally xeno-free matrices such 
as Cellstart, vitronectin, laminin, recombinant proteins and various synthetic matrices have 
been tested (Bergrström et al., 2011; Ausubel et al., 2011; Chen et al., 2011; Miyazaki et al., 
2012; Rodin et al., 2010; Mei et al., 2010; Lu et al., 2012). By suspension culture, the need for 
a matrix surface can be completely avoided (Zweigerdt et al., 2011), however shear forces can 
cause damage to the cells (Serra et al., 2012).  
To remove the serum-based products with batch-to-batch variation from the media, knockout 
serum replacement (KSR) medium has been developed and is now largely used in iPSCs 
generation in feeder cultures (Seki and Fukuda, 2015). Also, a chemically defined serum-free 
medium called mTESR1 was developed and is now the most widely published feeder-free 
medium for ESC- and iPSC cultures (https://www.stemcell.com/mtesr1.html, cited 7.5.2017). 
Although these are improvements compared to the traditional culture media, both contain 
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xenogenic compounds. Multiple completely xeno-free defined media such as Essential 8 
medium (E8), TeSR2 medium and Nutristem XF/FF medium are also available for successful 
generation of iPSCs (Chen et al., 2011; Bergström et al., 2011; Sugii et al., 2010). The benefits 
of especially E8 medium is also the lower cost, and the fact that the medium is composed of 
only 8 defined components (Chen et al., 2011).  
As well as the actual matrix and media used, also other factors can enhance reprogramming 
efficiency or cell survival in culture. Reprogramming in hypoxic conditions of 5% O2 rather 
than atmospheric 21%, increases the reprogramming efficiency 5-fold in both mice and human 
cells. When valproic acid is additionally used, the efficiency with mice cells increased as much 
as 200-fold. (Yoshida et al., 2009) L-Ascorbic acid (AA) has also been proven to promote iPSC 
growth and survival (Chen et al., 2011), in addition to various other small molecules presented 
in Table 1. Small molecules or hypoxia can be used to enhance reprogramming efficiency and 
help to improve the reprogramming of recalcitrant somatic cells. Yet another alternative would 
be to use embryonic stem cell -conditioned medium to induce reprogramming. (Malik and Rao, 
2013) 
Table 1. Small molecules and their targets to improve iPSC reprogramming efficiency  
(Modified from Malik and Rao, 2013) 
Treatment Process affected 
Valproic acid Histone deacetylase inhibition 
Sodium butyrate Histone deacetylase inhibition 
PD0325901 MEK inhibition 
A-83-01 TGFβ-inhibition 
SB43152 TGFβ-inhibition 
Vitamin C 
Enhances epigenetic modifiers, promotes survival by antioxidant 
effects 
Thiazovin ROCK inhibitor, promotes cell survival 
PS48 P13K/Akt activation, promotes glycolysis 
5% Oxygen Promotes glycolysis 
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2.2.4 Reprogramming methods 
After deciding on the cell type, reprogramming factors and culture conditions to be used, a 
suitable reprogramming method should be picked. The method of choice should also be 
considered by the downstream application, for example if aiming for clinical application of the 
produced cells, a foot-print free method of generating iPS-cells needs to be used. In regards, 
the reprogramming methods can be divided into two major classes: integrating and non-
integrating depending on whether the reprogramming factors are incorporated into the host cell 
genome during reprogramming or not (Gonzalez et al. 2011). Higher-quality iPSCs are 
produced by non-integrating methods since no danger of the reactivation of the pluripotency 
genes or insertional mutagenesis is present. Various reprogramming methods have been 
developed, and are outlined in Figure 2. 
 
Figure 2. Methods for generating induced pluripotent stem cells. (Lai et al., 2011) 
12 
 
2.2.4.1 Integrating viruses 
The first successful reprogramming reported used a retroviral transduction method (Takahashi 
and Yamanaka 2006) using Moloney murine leukaemia virus (MMLV)-derived retroviruses 
such as pMXs, pLib12 or pMSCV. These can infect dividing cells at an efficiency of even 90% 
(Gonzalez et al. 2011). Nonetheless reprogramming efficiencies using the Yamanaka-factors 
reported for human cells is between 0,01-0,02% (Menon et al., 2016). Another retroviral 
method used is transfection with lentiviruses derived from the human immunodeficiency virus 
(HIV). They have a higher infection efficiency and cloning capacity than the MMLV-
retroviruses. As it can infect both non-dividing and dividing cells, it soon became a more 
preferred method for generating iPSCs over the MMLV-retroviral method (Malik and Rao, 
2013). The higher efficiency has been reported to be between 0,1-2% (Gonzalez et al. 2011). 
Originally several different retroviruses all containing one reprogramming factor were 
generated. To achieve complete reprogramming the transfected cell needs to obtain each 
transcription factor from different retroviruses. This may lead to uneven stoichiometric 
quantities of the transcription factors in the cells, and low reprogramming efficiency since the 
cell may not obtain all transcription factors. Moreover, the major downside using retroviruses 
is that the viral transgenes have been reported to integrate randomly into the iPS-cell genomes, 
which may cause dysregulation of proto-oncogenes and insertional mutagenesis in the host cell 
genome (Gonzalez et al., 2011). With the use of multiple transcription factors also the risk of 
insertional mutagenesis increases. The other disadvantage with retroviruses concerns gene 
silencing. To achieve full reprogramming, the viral transgenes need to be silenced after iPSC-
formation (Hotta and Ellis, 2008), which is sometimes inefficient. Some genes may not even 
be silenced at all, and as the transgenes remain in the host cell genome they may be reactivated 
later point (Brouwer et al., 2016; Hu, 2014; Toivonen et al., 2013). 
The safety issues regarding retroviruses have been addressed by creating polycistronic 
lentiviruses. These contain all transcription factors in one vector, separated by self-cleaving 2A 
peptide sequences (Brouwer et al., 2014; Carey et al., 2009). This decreases the risk of 
insertional mutagenesis since fewer integration sites are introduced into the genome. Moreover, 
drug-inducible promoters have been created to establish a controlled expression of viral 
transgenes, as well as controlled silencing (Hockemeyer, 2008). Also, excisable lentiviruses 
utilizing the CreLoxP-system have been created (Sommer et al., 2010; Somers et al., 2010). In 
this system, the transfection cassette is flanked by loxP sites, and can be cleaved off by 
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introducing the Cre-recombinase after successful reprogramming. The Cre-recombination can 
be achieved by using picornaviral 2A plasmids or adenoviral Cre (Menon et al., 2016). Such a 
reprogramming construct called STEMCCA is now widely used with reprogramming 
efficiencies of 0,1-1,5% (Somers et al., 2010). However, although creating transgene-free 
iPSCs, this system still leaves a genomic scar (LoxP-site), causing possible insertional 
mutagenesis (Brouwer et al., 2016). The iPSCs generated this way will still be lacking in safety, 
especially for clinical purposes. 
2.2.4.2 Non-integrating viruses 
Because of the safety issues related with the use of retroviruses, other methods of generating 
footprint-free iPSCs have been developed. Non-integrating, viral methods include transfection 
with adenoviral or sendai-viral vectors. The reprogramming efficiencies using replication-
deficient adenoviruses have been very modest, 0,0002% with human cells (Zhou and Freed 
2009), and would need a lot more optimisation for it to have useful application in iPSC 
generation (Malik and Rao, 2013). An F-gene deficient form of the single-stranded, negative-
sense RNA sendai virus have been shown to infect a wide range of host cells (Tokusumi et al., 
2002), and produces protein in large quantities (Malik and Rao, 2013). The virus replicates in 
the host cell cytoplasm, which makes it an appealing candidate for reprogramming since it does 
not integrate to the host cell genome. Moreover, the viral RNA will usually be completely lost 
at approximately p. 10, creating footprint-free iPSCs. (Malik and Rao, 2013). The viral particles 
can also be removed by antibody-mediated negative selection against surface protein HN on 
the virus (Fusaki et al., 2009).  
A modified sendai-virus with mutations on polymerase-related genes has been created, and as 
a result temperature-sensitive viruses that can be removed by a temperature increase are 
achieved (Brouwer et al., 2016). Traditional methods using four different viruses each 
containing one of the four reprogramming factors are in use, but a novel system containing 
KLF4, OCT4 and SOX2 has been developed, and showed an increase in the reprogramming 
efficiency when used together with a virus containing C-MYC (Fujie et al., 2014). Another 
sendai-virus method based on the temperature-sensitive variant has been developed, and 
contains all the four transcription factors in one virus to ensure stoichiometric amounts of all 
four transcription factors (Nishimura et al., 2011). Human fibroblasts and blood cells have been 
reprogrammed with efficiencies of 0,1% and 1% (Fusaki et al., 2009; Seki et al., 2010; Ban et 
al., 2011), comparable to the lentiviral method but producing iPSCs of higher quality.  
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2.2.4.3 PiggyBac 
PiggyBac (PB) is a mobile linear genetic element, a transposon, that can transpose between 
chromosomal TTAA sites with the help of a transposase. The PB-transposase recognises 
specific inverted terminal sequences in the transposon, and integrates them between the TTAA 
sites. Usually the system consists of a donor plasmid comprising the transposon with the 
transgenes and a helper plasmid expressing the transposase (Gonzalez et al., 2011). After 
reprogramming, the PB-transposase can be used to cleave out the transposon, leaving no 
genomic scar unlike the Cre/loxP-system. (Menon et al., 2016) In addition to creating footprint-
free iPSCs, the PB-transposon can be used to reprogram any type of cell, and is a completely 
xeno-free system (Brouwer et al., 2016). Successful reprogramming of human embryonic 
fibroblasts using the PB containing the Yamanaka-factors resulted in efficiencies of 0,02-0,05% 
(Kaji et al., 2009). However, the full removal of the transposon has not been demonstrated. 
Since the PB-transposon is integrated momentarily into the host cell genome, it can integrate 
into a transcriptional region and hamper the expression of endogenous genes. The human 
genome also contains endogenous PB-transposase sites, which may respond upon introduction 
of the PB-transposon. (Brouwer et al., 2016) Moreover, some studies have suggested that 
removing large copy numbers of the transposon might be difficult. (Menon et al., 2016). 
2.2.4.4 Minicircle or plasmid DNA 
The reprogramming factors can also be introduced to the host cells as DNA molecules as 
plasmids or minicircle DNA, usually with electroporation (Han et al., 2015). Compared to the 
viral gene delivery, these methods are relatively simple and fast, since no laborious production 
of viral particle is required. In addition, the electroporation process is extremely quick and 
relatively inexpensive.  
The minicircle is a supercoiled small DNA molecule consisting only of a eukaryotic promoter 
and the expressed cDNA (Malik and Rao, 2013). Unlike traditional plasmids, they have no 
bacterial backbone and might be less immunogenic (Brouwer et al., 2016). The reprogramming 
efficiency using minicircle vectors are, however, very low. For example, Narsinh et al were 
able to reprogram human adipose stromal cells with a modest efficiency of 0.005% (Narsinh et 
al., 2011). Usually the host cells need to be transfected multiple times to achieve full 
reprogramming but recently a CoMIP minicircle vector needing only one transfection was 
constructed by Diecke et al. (Diecke et al., 2015). The construct was able to achieve successful 
reprogramming, albeit with a very low efficiency.  
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Another way to achieve reprogramming is by using an episomal plasmid based on the Epstein-
Barr Nuclear Antigen-1 (EBNA-1).  Usually the plasmids are expressed only transiently, but 
the oriP-EBNA-1 plasmid allows for a stable expression of reprogramming factors for a longer 
period. Thus, only one transfection is needed. The oriP-EBNA1-plasmid can attach to the host 
chromatin, where it is replicated along with the chromosomal DNA once per each cell cycle. 
Although attached to the chromosomal DNA, the use of an oriP-EBNA1 plasmid is a non-
integrating method generating iPSCs. However, as with the minicircle DNA, the efficiencies of 
iPSCs generation remain low. By transduction of three oriP-EBNA1 plasmids containing the 
OCT4–SOX2–NANOG–KLF4, OCT4–SOX2–SV40LT–KLF4 and C-MYC–LIN28 genes, 
fibroblasts were reprogrammed at a very low efficiency (Yu et al., 2009; Schlaeger et al., 2015). 
The efficiency of the method could be enhanced considerably by suppressing p53 and using a 
non-transforming L-MYC instead of the oncogenic C-MYC (Okita et al., 2011). A study by Hu 
et al. also showed that no plasmid was anymore detectable at passage 15, suggesting that the 
oriP-EBNA1-plasmid will be lost during time (Hu et al., 2011). Regardless of the low 
efficiencies, the episomal reprogramming has become one of the preferred non-integrating 
method for generating iPSCs owing to the high quality of the generated iPSCs (Brouwer et al., 
2016). 
2.2.4.5 RNA delivery 
In order to completely avoid the introduction of genetic or other viral material into the host cell, 
mRNA can be used (Warren et al., 2010). By direct delivery of synthetic mRNA containing the 
Yamanaka-factors Warren et al. could reprogram human fibroblasts at a high efficiency of 
1,4%. The mRNA has to be processed with phosphatase to create capped 5’ end, and the 
ribonucleoside based cytidine and uridine replaced by modified 5-methylcytidine and 
pseudouridine to reduce immune responses. When also including LIN28, culturing at 5% O2 
and valproic acid, the reprogramming efficiencies reported were as high as 4,4% (Warren et al., 
2010). Although efficient and totally footprint-free, this method is very labor-intensive due to 
short half-lives of mRNA-molecules (Brouwer et al., 2016). Although the half-life can be 
increased by adding a 5’-guanine cap (Warren et al., 2010), constitutive addition of mRNA has 
to be conducted for 7 days. Commercial products for reprogramming are, however, available 
(Malik and Rao 2013).  
In addition to mRNA, also miRNAs have been used to achieve successful reprogramming as 
discussed in chapter 2.2.3. By choosing miRNAs that are strongly expressed in ESCs, 
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successful reprogramming has been achieved by various groups. The expression of mir302/367 
sequences delivered with a lentivirus was able to reprogram commercial human fibroblasts at a 
high efficiency of even 10% (Anokye-Danso et al., 2011). In another study, human dermal 
fibroblasts and stromal cells were reprogrammed by transfection of miRNAs mir-200c, mir-
302s and mir-369. Reprogramming efficiency was, however, extremely low, 0,002%. As with 
traditional mRNA delivery, delivering the miRNAs to the cells as such also requires multiple 
transfections making the process more laborious. (Miyoshi et al., 2011) 
2.2.4.6 Protein delivery 
One interesting approach of generating iPSCs without viral or other genomic contamination is 
the introduction of pluripotency factors as proteins into the cells. Proteins can be delivered to 
cells fused with peptides such as HIV transactivator of transcription or polyarginine (Inoue et 
al., 2006; Michiue et al., 2005; Wadia and Dowdy, 2002). In a study by Kim et al., human 
fibroblasts were successfully reprogrammed with poly-arginine-tagged Yamanaka-factor 
proteins, albeit with a low reprogramming efficiency of 0,001% (Kim et al., 2009). Although 
plausible, the low efficiency and difficulty and labor-intensity of producing and purifying large 
amounts of bioactive proteins makes this strategy ill-suited for routine reprogramming 
(Gonzalez et al., 2011). As with synthetic mRNA, multiple rounds of transfection of protein is 
needed to maintain high enough levels of transcription factors for reprogramming (Brouwer et 
al., 2016). 
2.2.5 Reprogramming phases 
The reprogramming mechanisms still remain somewhat unknown. The first challenge of the 
early iPSC-research was to define if the cells truly resemble ESCs. This was in fact proven to 
be true morphologically, functionally, as well as transcriptionally and epigenetically (David 
and Polo, 2014; Maherali et al., 2007; Mikkelsen et al., 2008; Okita et al., 2007; Takahashi et 
al., 2007; Wernig et al., 2007). The epigenetic differences observed in some iPSC-lines 
compared to ESC-lines were shown to be caused mainly by the reprogramming method used 
(Yamanaka 2012), and can be diminished during passaging of the iPSCs (Chin et al., 2009; 
Nishino et al., 2011; Polo et al., 2010). Based on large transcriptomic studies of fibroblast 
reprogramming, Samavarchi-Tehrani et al. divided the reprogramming into three distinct 
phases: initiation, maturation and stabilization (Samavarchi-Tehrani et al., 2010), depicted in 
Figure 3. Each phase consists of typical events and is characterised by specific molecular 
markers. 
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Figure 3. Phases of reprogramming. Reprogramming of iPSCs is thought to consist of three 
distinct phases: initiation, maturation and stabilisation, all characterised by specific events and 
markers (David and Polo, 2014) 
So far, the initiation phase is the most well-known (David and Polo, 2014). The most used cell 
type to study the mechanisms are fibroblasts, which in the initiation phase are characterised by 
a change in the morphology from mesenchymal-to-epithelial transition (MET). Molecular 
markers for this event includes loss of transcription factors Snai1/2 and Zeb1/2 (David and 
Polo, 2014; Mikkelsen et al., 2008; Stadtfeld et al., 2008; Samavarchi-Tehrani et al., 2010), and 
subsequent gain of epithelial markers Cdh, Epcam or the epithelia-associated miRNA-200 
family (Li et al., 2010; Samavarchi-Tehrani et al., 2010). Other markers, such as Thy1 and 
CD44 are lost, and pluripotency markers alkaline phosphatase and stage-specific embryonic 
antigen (SSEA)-1 gained (O'Malley et al., 2013; Hansson et al., 2012; Polo et al., 2012; 
Samavarchi-Tehrani et al., 2010; Brambrink et al., 2008; Mikkelsen et al., 2008; Stadtfeld et 
al., 2008). Also, two kinases have been identified as likely barriers of reprogramming: Tesk1 
and LIMK2. When TESK1 was inhibited with a siRNA, the reprogramming efficiency was 
significantly improved (Sakurai et al., 2014).  
In addition to the MET-associated events, also the acquisition of ESC-like properties including 
proliferation and resistance to apoptosis or cell senescence are important features taking place 
during the initiation phase (David and Polo, 2014; Marion et al., 2009a; Utikal et al., 2009b; 
Mikkelsen et al., 2008). Interestingly, although most the cells have been shown to be able to 
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initiate reprogramming, only a small portion of these cells can undergo full reprogramming 
(Polo et al., 2012). The mechanism is not known, but one proposed theory is the innate 
immunity, that would trigger protein degradation in the reprogramming-refractive cells (David 
and Polo, 2014). 
The changes in gene and protein expression during the initiation phase suggests a hierarchical 
network of events caused by the interaction of the transcription factors, co-factors and the 
chromatin. One mechanism of how this happens was proposed by Soufi et al.: the high 
concentration of the transcription factors can bind to more genes than they would with 
physiological concentrations, thus inducing reprogramming (Soufi et al., 2012). The study also 
suggests that the transcription factors Oct4, Sox2 and Klf4 bind to inactive DNA regions, while 
Myc only binds to accessible regions, serving as a transcriptional response amplifier in the 
activated DNA regions (Lin et al., 2012; Nie et al., 2012). Myc is thought to be responsible for 
the induction of MET, while the other transcription factors mostly serve as pioneers (Soufi et 
al., 2012; Sridharan et al., 2009) At the chromatin level changes occur only as histone 
modifications, but not as epigenetic changes (David and Polo, 2014; Polo et al., 2012). 
The transition from the initiation to the maturation phase is considered as the major bottleneck 
phase of reprogramming (David and Polo, 2014). The maturation phase is characterised by the 
activation of the first pluripotency genes (Polo et al., 2012; Samavarchi-Tehrani et al, 2010). 
The first markers that can be detected during this phase include, Fbxo 15, Sall4 and endogenous 
Oct4. After this, also Nanog and Esrrb can be detected. Fbxo15 alone is however a poor marker, 
since it has also been shown to be active in only partially reprogrammed cells (David and Polo, 
2014; Takahashi and Yamanaka, 2006). More reliable markers used since have been Nanog and 
Oct4 (Maherali et al., 2007; Okita et al., 2007), although notable that none of these factors alone 
is either a guarantee of complete programming (Buganim et al., 2012).  At the verge of entering 
the stabilisation phase, factors such as Sox2 and Dppa4 can be detected (Buganim et al., 2012; 
Polo et al., 2012; Samavarchi-Tehrani et al., 2010; Stadtfeld et al., 2008). The acquisition of 
pluripotency markers is thought to happen in a sequential way with some markers expressed 
earlier in the maturation phase, and others first late in the stabilisation phase (Polo et al., 2012; 
Buganim et al., 2012). 
The stabilisation phase includes the changes that happens in the iPSCs after becoming 
pluripotent (Ho et al., 2011). In this phase the cells acquire the full pluripotency signature, and 
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in the end a pluripotent state that is maintained without the help of ectopic expression of the 
reprogramming factors (Okita et al., 2007; Wernig et al., 2007). The characterisation of iPSCs 
is done during this phase (David and Polo, 2014).  In mouse iPSCs, the inactivated X 
chromosome is rendered active again during the stabilization phase (Stadtfeld et al., 2008). The 
phase is also characterised by many epigenetic changes, many of which remain poorly known. 
One important notion in mouse cells is the elongation of telomeres into an embryonic level 
(Stadtfeld et al., 2008; Marion et al., 2009b). During extended periods in culture, the iPSCs also 
become epigenetically more like ESCs (Nishino et al., 2011; Chin et al., 2009; Polo et al., 2010), 
while at the same time losing the epigenetic memory of the donor cell type. The epigenetic 
resetting can also be enhanced using 5-aza-deoxycytidine (AZA). (Kim et al., 2011; Ohi et al., 
2011; Polo et al., 2010). At least one DNA methylation factor, AID, has been shown to be 
involved in the epigenetic reset (Bhutani et al., 2010; Kumar et al., 2013), but possibly also the 
TET-family and DMNTs play a role in this event (Polo et al., 2012). Further studies to unveil 
the mechanisms underlying the epigenetic remodeling are, however, required (David and Polo, 
2014).   
2.2.6 Characterisation of induced pluripotent stem cells 
To assess the quality of the generated iPSCs, they must be characterised on many different 
levels. These levels and methods to study them are presented in Figure 4.  As the first sign of 
iPSC formation is the typical morphology: the PSC morphology is defined by compact colonies 
with defined borders, having small cells with a high nucleus to cytoplasm ratio and large 
nucleoli (Thomson et al., 1998). For feeder-free monolayer cultures, the morphology is less 
defined (Brouwer et al., 2016). In addition to the typical morphology, iPSCs proliferate 
extensively in cell culture (Thomson et al., 1998). 
In addition to morphological characterisation, many cellular and molecular level assays are used 
to characterise the cells (Brouwer et al., 2016). iPSCs are fully reprogrammed only when the 
transgenes are silenced and endogenic pluripotency genes turned on (Hotta and Ellis, 2008). 
Thus, the silencing of transgenes needs to be confirmed. The expression of various pluripotency 
markers (presented in Figure 4) is assessed by RT-PCR at mRNA level and at protein level by 
immunocytochemistry. The presence of one marker is not necessarily an indication of complete 
reprogramming (Buganim et al., 2012), and usually many of these markers are used. Since 
pluripotent stem cells are also characterised by a high enzymatic activity of phosphatases, an 
alkaline phosphatase assay is often performed (Brouwer et al., 2016). 
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 Figure 4. Characterisation of iPS-cells. To verify the pluripotency and full reprogramming of 
the generated iPS-cells, many different methods can be used. While it’s not necessary to 
perform all methods, no method alone can confirm good quality of the iPSCs. (Brouwer et al., 
2016) 
The differentiation potential of the iPSCs is usually assessed in vitro and in vivo. The pluripotent 
stem cells should be able to differentiate into all three germ layers. An in vitro assay of the 
differentiation potential includes an embryoid body (EB) assay, usually performed in floating 
culture (Yu et al., 2007; Takahashi and Yamanaka 2006; Itskovitz-Eldor et al., 2000). In vivo –
differentiation potential is usually assessed by a teratoma formation assay usually performed 
by injection of cells into immunodeficient mice (Thomson et al., 1998). The detection of the 
different germ layer can be subsequently verified by RT-PCR of germ-layer specific genes. 
Since genetic and epigenetic changes can occur during the generation of iPS-cells (Doi et al., 
2009; Kim et al., 2010; Polo et al., 2010), the genetic and epigenetic profiles of the iPSCs should 
also be studied. Large chromosomal aberrations can be detected with a karyotyping analysis. 
Since DNA methylation is an indicator of gene silencing, the methylation states of the stem cell 
specific –endogenes and donor-cell type –specific genes can be assessed. For example, 
NANOG and OCT4 are unmethylated during reprogramming, which indicates their active 
transcription (Mikkelsen et al., 2008). During reprogramming, the somatic donor cell -specific 
genes should also be silenced, indicated by methylation. At the same time, pluripotency genes 
should be activated, indicated by demethylation. (Brouwer et al., 2016) 
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While many different assays can be used to characterise the created iPSCs, no method alone is 
sufficient to confirm good quality of the iPSCs. Thus, a combination of methods should be 
used. (Brouwer et al., 2016) 
2.3 Cardiomyocyte differentiation 
The generation of cardiomyocytes from iPSCs is of interest for multiple reasons. Since cardiac 
development cannot be studied in the developing embryos, the cardiogenesis can be studied in 
vitro with the help of iPSCs. Moreover, these cardiac in vitro -models can also be useful in 
basic research of cardiac function such as electrophysiology or protein chemistry. Genetic 
cardiac disorders can be studied by the generation of patient- and disease-specific iPSC-lines 
from patients with these disorders. Moreover, these models can be used for drug and toxicity 
screening of different compounds. In the more distant future, iPSC-derived cardiomyocytes can 
also be used in regeneration and cell therapies, such as repair of the human heart after a 
myocardial infarct. (Mummery et al., 2012)  
During extended periods of culture, the cells gain a more mature phenotype described by the 
loss of proliferative ability, elongation, subtype specific action potential profile, changes in 
gene expression and an increased beat frequency. Even so, the cells resemble more fetal than 
adult cardiomyocytes. (Batalov and Feinberg, 2015) To develop better-quality cardiomyocytes 
for research and therapeutic purposes, the maturation process and factors involved need to be 
studied. In addition, methods to apply these to iPSCs-derived cardiomyocytes also have to be 
developed.  
2.3.1 Differentiation methods 
The cardiomyocyte differentiation protocols for iPS-cells were first established for ES-cells, 
and later adapted to iPSCs (Batalov and Feinberg, 2015). Currently, differentiation methods 
can be divided into three categories: 1) co-culture with mouse endoderm-like (END-2) stromal 
cells 2) differentiation in EBs in suspension culture and 3) 2D monolayer differentiation 
(Batalov and Feinberg, 2015). All methods however, produce cardiomyocytes with an 
immature phenotype when compared to adult cardiomyocytes. The cells can be matured further 
by various methods. These methods include prolonged time in culture (for even longer than a 
year), electromechanical stimulation, treatment with tri-iodo-L-tyronine, transgenic expression 
of cardiac-specific proteins or by co-culturing them with non-cardiomyocytes. (Batalov and 
Feinberg, 2015). 
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2.3.1.1 Co-culture with END-2 cells 
The cardioinductive signals during embryonic development arise likely from a direct cell-cell 
contact or by factors secreted from the embryonic endoderm (Rajala et al., 2011). The END-2 
cells from mouse P19 embryonal carcinoma are used to mimic the embryonal endoderm, and 
to drive the differentiation into cardiomyocytes. The differentiation efficiency is usually fairly 
low, but can be improved by the use of AA (Passier et al., 2005; Takahashi et al., 2003), or in 
the absence of serum (Rajala et al., 2011). With the use of a p38 MAPK inhibitor, an efficiency 
as high as 25% could be achieved (Graichen et al., 2008). Factors identified from END-2 that 
enhance the cardiomyocyte differentiation, can also be used to further enhance the 
differentiation efficiency (Rajala et al., 2011). Advantages of the END-2 differentiation method 
are its inexpensiveness and simplicity (Batalov and Feinberg, 2015). 
2.3.1.2 Embryoid body differentiation 
The EB differentiation method is a method that mimics the early embryonic development 
(Batalov and Feinberg, 2015). It relies on either spontaneous differentiation or a combination 
of physical and chemical factors to direct the differentiation of iPSCs into cardiomyocytes. The 
spontaneous differentiation is performed in suspension culture, where the iPSCs aggregate to 
form the EBs and spontaneously differentiate into a myriad of cell types. Inside the formed 
EBs, contracting areas with functional properties of cardiomyocytes are found, and can be 
isolated and re-plated for further differentiation. The efficiency obtained by this method is, 
however, low with under 10% of the cells differentiating into cardiomyocytes. (Rajala et al., 
2011) Spontaneously formed EB-aggregates vary in size and morphology. The variation 
between the EBs can, however, be decreased by hanging-drop and forced-aggregation methods 
(Yoon et al., 2006). The differentiation towards cardiomyocytes can be further enhanced by the 
addition of growth factors, morphogenes or by transgenic modifications (Rajala et al., 2011). 
At least with ES-cells, the efficiency has been shown to significantly increase by the addition 
of 5-AZA (Yoon et al, 2006). In addition, low oxygen tension using a 4% O2 level rather than 
the atmospheric 20% yielded a higher amount of cardiomyocyte differentiation (Niebruegge et 
al., 2009). Also electrical stimulation has been applied resulting in increased differentiation 
efficiency (Serena et al., 2009).  
2.3.1.3 2D monolayer culture 
The 2D monolayer differentiation method is based on guidance by small molecules and growth 
factors added to the culture medium. In comparison to the EB and END-2 methods, the 2D 
monolayer culture method also results in more mature cardiomyocytes. Also cardiomyocytes 
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showing signs of subtype specification have been created by this method with cardiomyocyte 
yields as high as 85- 95%. (Batalov and Feinberg, 2015) The first paper reporting monoculture 
differentiation using hESCs was published in 2007 (Laflamme et al., 2007). At first, a confluent 
monolayer was cultured on Matrigel in MEF-conditioned medium. After this, the medium was 
changed into a chemically defined RPMI-B27 medium complemented with Activin-A, bone 
morphogenetic protein (BMP)-4 at precise time points, followed by culture in pure RPMI-27 
for two weeks. With this method, over 30% of the cells differentiated into spontaneously 
beating cardiomyocytes. However, a lot of variation existed between different cell lines. In 
2012 Lian et al. could improve the monolayer culturing method by stimulation of Wnt (a 
mammalian ortholog of the Wingless gene observed in Drosopohila) /β-signaling with the 
addition a GSK3-inhibitor at the beginning of differentiation. They also noted that insulin in 
the B27 medium supplement serves as an inhibitor for cardiomyocyte differentiation. The 
adding of GSK3-inhibitor and removal of insulin led to both increased consistency between 
lines and an increased differentiation efficiency of 82-95%. (Lian et al., 2012) Since the B27 
medium contains factors with not yet fully defined effects on the differentiating cells, media 
containing of only a few known components have been tested lately. For example, E8 media 
also used with iPSCs has proven efficient, as well as a CDM3 medium containing only 3 
components. These media also decrease the costs of differentiation. (Batalov and Feinberg, 
2015) 
2.3.2 Cardiogenesis and iPSC-differentiation mechanisms 
One of the first events in embryonic development is the formation of the heart (Rajala et al., 
2011). Heart development requires precise migration, proliferation and differentiation of many 
cell types originating from different embryonic origins. These processes need to be tightly 
orchestrated in a timely manner by different molecular pathways. (Roche et al., 2013) Studies 
with mice and chick embryos have shown that the heart tissue is formed from three major 
mesoderm-originated lineages including the cardiac myocyte, the vascular smooth muscle, and 
the endothelial cell lineages. (Rajala et al., 2011) Early in gastrulation, the cardiac progenitor 
cells arise from the anterior lateral mesoderm and migrate through the primitive streak. These 
early progenitor cells are comprised of a cell population called the cardiac crescent. Positive 
and negative signals from the underlying endoderm are responsible for inducing cardiac 
specification of the cardiac crescent. One of the earliest markers for cardiac specification is 
Wnt.  (Roche et al., 2013) The progenitors that form the heart fields coalesce and form two 
parallel vessels, which are in turn fused to form the cardiac tube. After rightward looping and 
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a series of septation and fusion events, the four-chambered heart forms and matures further 
before birth. It is first after birth that the cardiomyocytes undergo terminal differentiation and 
lose their ability to proliferate. (Roche et al., 2013) The events leading to the generation of the 
heart are controlled by many transcription factors. (For a more detailed review of the factors 
and their role in cardiogenesis, see Roche et al., 2013) 
The differentiation of iPSCs into cardiomyocytes in vitro mimics the cardiogenesis observed in 
the embryo. The well-orchestrated cardiac development includes the expression of multiple 
signal transduction proteins and transcription factors, the most studied of which are 
Wnts/Nodal, BMPs and FGFs (Rajala et al., 2011). In addition to the right factors, also their 
timely manner is of importance, and certain factors can serve as inhibitors during a certain 
period of time, and as activators at another time point. Thus, the timing of their addition to 
guide the differentiation of iPSCs is of crucial importance. Cardiomyocytes can be 
differentiated in four steps: 1) formation of mesoderm, 2) the patterning of mesoderm toward 
anterior mesoderm or cardiogenic mesoderm, 3) formation of the cardiac mesoderm and 4) 
maturation of early cardiomyocytes (Rajala et al., 2011). The steps and typical markers 
observed during those steps are outlined in Figure 5. 
The first step has been well characterised, and many studies show that Wnts, BMPs and 
transforming growth factor (TGF) β- family member Nodal (or Activin A) are important in 
inducing mesoderm. The two latter steps are less well defined for human iPSCs. However, 
studies with chick and xenopus embryos suggest that Nodal and Wnt inhibition plays a role in 
cardiomyocyte formation. Thus, Dickkopf-1, a Wnt antagonist, is usually used in differentiation 
protocols. Another important signal pathway is one mediated by a transmembrane receptor 
called Notch. It induces the expression of many growth factors including Wnt5a, BMP6, and 
Sfrp1 that in turn increase the number of cardiac progenitors. The last step, where committed 
cardiac progenitors mature into beating cardiomyocytes, usually occurs spontaneously in vitro. 
(Rajala et al.,2011)  
 
Figure 5. The steps in cardiac differentiation of iPSCs and typical markers expressed during 
those steps. (Rajala et al., 2011) 
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In addition to the various growth factors and transcription factors, miRNAs have been shown 
to affect the differentiation process. miR-1, miR-133, miR-206, and miR-208 are expressed in 
the heart (Callis et al., 2008; van Rooji et al., 2008), while miR-143 and miR-145 are also 
thought to have an important role in cardiomyogenesis. (Wang et al., 2008). For example, miR-
1 was able to increase the amount of beating aggregates in EB differentiation. MiR-133 also 
promotes the differentiation of the early mesoderm, but after that serves as an inhibitor of 
cardiac commitment. (Ivey et al., 2008) Better knowledge of the later steps in cardiomyocyte 
differentiation could help in identifying factors that could increase differentiation efficiency 
and further enhance cardiomyocyte maturation. 
2.3.3 Characterisation of cardiomyocytes 
To characterise the generated cardiomyocytes, the expression of specific molecular markers, 
structure and functionality can be studied (Rajala et al., 2011). The first sign of cardiomyocyte 
differentiation in vitro is the appearance of spontaneously beating cells (Mummery et al, 2003). 
The cardiomyocytes originate from a mesodermal origin, and as an early marker of the 
mesoderm and cardiac lineage differentiation, Brachury T is generally used (Kispert and 
Herrmann, 1994). Other early markers of cardiomyocyte differentiation are the upregulated 
gene expression of transcription factors Islet-1, mesoderm posterior 1 and 2, GATA4-binding 
protein and T-box transcription factor 6 (Graichen et al., 2008; Yang et al., 2008; Brand, 2003). 
The expression of these genes can be studied at mRNA level by RT-PCR.  
Also several structural proteins can be used as markers of cardiomyocyte differentiation, and 
stained by immunocytochemistry. Markers of a more mature phenotype include cardiac 
Troponin T, cardiac Troponin I, cardiac α-actinin, desmin, tropomyosin and atrial- and 
ventricular myosin light chains (Kehat et al., 2001; Mummery et al, 2003; Rajala et al., 2011). 
In addition, connexin proteins present in gap junctions, such as connexin 43, 40 and 45 can be 
used as markers (Gaborit et al. 2007), as well as ion channel markers hERG and KCQN1. Also 
natriuretic peptide can be used as a marker of cardiomyocyte differentiation (Rajala et al., 
2011).  
In addition to visual and biochemical characterisation, the functionality of the differentiated 
cardiomyocytes can be characterised by studying the electrophysiology of the cells. Action 
potentials of single cardiomyocytes can be studied with patch-clamp analysis, and immature 
iPSC-derived cardiomyocytes are characterised by a slower action potential upstroke and a 
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relatively depolarised maximum diastolic potential (Rajala et al., 2011). The cardiomyocytes 
also express altered Ca2+ handling (Batalov and Feinberg, 2015), that can be studied with 
microelectrode array (MEA). 
Altogether, the cardiomyocytes differentiated from iPSCs all express an immature phenotype 
when compared to adult cardiomyocytes. The more fetal-like phenotype expressed is 
characterised by a smaller length-to-width aspect ratio, mononuclearity, poor sarcomere 
organisation and fewer mitochondria when compared to adult cardiomyocytes. (Robertson et 
al., 2013) 
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3. Research objectives 
The first aim of this study was to establish and characterise new iPSC-lines generated either by 
an episomal or a sendai-viral method and cultured in traditional conditions including mouse 
embryonic feeders and KSR-medium supplemented with b-FGF. A comparative view was 
maintained between the sendai-virally and episomally derived lines from the same patients. To 
assess the effect of the generation method on cardiomyocyte differentiation efficiency, two of 
these established and characterised lines from the same patient were differentiated into 
cardiomyocytes by an END-2 co-culture system for comparison. 
Traditional culturing of iPSCs includes undefined and xenogenic components, that pose issues 
especially for generating GMP-standardised methods for iPSC-generation and maintenance, as 
well as for possible clinical use of the generated iPS-cells. The other aim of this study was to 
establish and maintain iPSCs in feeder-free conditions on a Geltrex®-matrix in mTeSR1 
medium. Comparison of the reprogramming efficiencies between all episomally derived lines 
(both MEF-cultured, and the Geltrex®-lines) was also performed. 
The last aim was to study the activation of pluripotency genes by real-time qPCR from mRNA 
samples collected from an earlier and later passages. As the activation of endogenous 
pluripotency genes is thought to be a slow process (David and Polo, 2014), the genes were 
studied to see at which passage they are upregulated. Comparison was also done to study the 
differential expression of the pluripotency genes between patients. 
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4. Materials and Methods 
4.1 Cell lines 
All cell lines used in this study were newly reprogrammed from somatic patient cells. The cells 
used for reprogramming were dermal fibroblasts isolated and cultured from skin biopsies from 
patients with cardiac diseases. The fibroblasts were reprogrammed either with a Sendai-viral 
method or an electroporation method, and cultured on mouse embryonic feeders (MEFs) or a 
cell-free Geltrex®-matrix. Lines used for this study were S1M, S2M, S3M, E1.1M-E1.4M, 
E2.1M-E2.4M, E3.1M-E3.2M, E4G and E5G. The first letter of the cell line refers to the 
reprogramming method (sendai virus=S and electroporation= E, respectively) and the latter for 
the culturing method (MEFs=M and feeder-free Geltrex®=G). Cell line numbers are patient 
specific, and all in all lines from five different patients were studied. The studied sendai-lines 
(S1M-S3M) were obtained from the lab technician. 
4.2 Reprogramming of patient fibroblasts 
Initial reprogramming for electroporation lines E1.4M-E3.2M was performed by PhDs Leena 
Viiri and Stephano Manzini. 600 000 fibroblasts (500 000 for lines E4G and E5G) were 
transfected with integration free, episomal plasmid vectors pCXLE-hOCT3/4-shp53-F; 
pCXLE-hSK; pCXLE-hUL and pCXWB-EBNA1 (Addgene) containing pluripotency genes L-
MYC, OCT3/4, SOX2 and KLF4 (plasmid constructs presented in Appendix A, Okita et al. 
2011). For transfection, the plasmids were used in equimolar amounts (1:1:1:1), i.e. 3 ug of 
each plasmid, except, 1,7ug of the smaller plasmid pCXWB-EBNA1. Transfection was 
conducted with the 4D-Nucleofector™ System (Lonza) according to manufacturer’s 
instructions.  
Transfected cells were cultured overnight in medium containing Dulbecco’s modified Eagle’s 
medium (DMEM, Lonza) supplemented with 10% fetal bovine serum (FBS, Gibco by Life 
Technologies) and 1% L-glutamine (Gibco by Life Technologies). Medium was changed the 
next day using same basic fibroblast medium supplemented with 1% Pen-Strep (Sigma 
Aldrich). Cells were incubated for 1 week at +37°C and 5% CO2. After this cells were 
trypsinised (Lonza), counted and re-plated at a density of 200 000/well on sterile 6-well plates 
(Greiner CELLSTAR®, Sigma-Aldrich). Transfected cells co-cultured with mouse embryonic 
feeder cells were plated and maintained on plates containing feeder cells (as describer in chapter 
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4.3.1) and feeder-free cultures were maintained on Geltrex® (ThermoFisher Scientific)-coated 
plates (as describer in chapter 4.3.2). Cells were cultured at +37°C and 5% CO2 until colony 
picking. 
Sendai-lines S1M-S3M were reprogrammed by the lab technician. 150 000 fibroblasts were 
transduced with the CytoTune®-iPS Sendai Reprogramming Kit (Invitrogen) containing F-gene 
deficient Sendai-viruses expressing the four Yamanaka factors. The reprogramming was 
conducted according to manufacturer’s instructions with a MOI of 1.25. After transduction, the 
sendai-lines were treated similarly to electroporated MEF-grown lines. 
3–4 weeks after the transfection/transduction individual iPSC-colonies had formed and were 
picked onto 24-well plates before being transferred onto 6-well plates one week later.  New 
iPSC lines were established from the colonies that survived after picking, and maintained as 
described in chapter 4.3.1. 
4.3 Maintenance of induced pluripotent stem cells  
4.3.1 iPS-cell co-culture with mouse embryonic feeder cells 
iPS-cells were cultured on sterile 6-well plates (Greiner CELLSTAR®, Sigma-Aldrich) at 
+37°C and 5% CO2 in 3 ml of KSR-medium ((KnockOut™ Dulbecco’s Modified Eagle 
Medium (KO-DMEM); Gibco by Life Technologies) supplemented with 20% KnockOut™ 
Serum Replacement (KO-SR; Gibco by Life Technologies), 2 mM non-essential amino acids 
(100x MEM NEAA; Gibco by Life Technologies), 1% L-glutamine (Sigma Aldrich), 1% 
Penicillin Streptomycin (Pen-Strep; Sigma Aldrich), 0.1 mM β-mercaptoethanol (β-ME; Sigma 
Aldrich) and 4 ng/ml of β-FGF (Peprotech)) per well. Half of the medium was changed every 
2–3 days. To confirm the undifferentiated status, the cells were visualised with light microscopy 
at least every other day. 
Cells were passaged once a week. One day prior to passaging, wells on a standard 6-well plate 
were coated with 0,1% gelatin (Type A from porcine skin, Sigma) and incubated for 1 hour at 
+37°C. Excess gelatin was removed and inactivated MEF cells (Mitomycin-C treated, Applied 
StemCell, Inc.) seeded at a density of 250 000 cells/well. Feeder cells were cultured overnight 
at +37°C and 5% CO2 in 3 ml of fibroblast medium containing DMEM supplemented with 10% 
FBS (Gibco by Life Technologies), 1% L-glutamine (Gibco by Life Technologies) and 1% Pen-
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Strep (Sigma Aldrich). The attachment of the feeder cell layer was confirmed with light 
microscopy before plating of the iPS-cells. 
The passaging of the iPS-cells was done by first removing the old feeder cell layer by scraping 
under the light microscope with a pipette tip. The intact iPS-cell colonies were then treated with 
1 ml of KSR-medium supplemented with 1 mg/ml collagenase IV (Gibco by Life Technologies) 
per well for 4-5 min at +37°C. After incubation, colonies were scraped into fresh KSR-medium, 
pipetted gently up-and-down a few times and part of the cell suspension was transferred onto 
new 6-well plates coated with a feeder layer. Cell attachment was confirmed the next day with 
light microscopy.  
Throughout the experiment, stocks of lines were made by freezing colonies in freezing medium 
containing 10% dimethyl sulfoxide (DMSO; Sigma Aldrich) and 90% FBS (Gibco by Life 
Technologies). After being frozen down in isopropanol chambers at -70°C, the cells were stored 
in liquid nitrogen. 
4.3.2 iPS-cell culture on feeder-free substrate 
iPS-cells cultured on feeder-free Geltrex® substrates were cultured on similar 6-well plated as 
MEF-cultured cells. 3 ml of mTeSR™1 basal medium (STEMCELL™ Technologies) 
supplemented with 10% of 5x mTesR supplement (STEMCELL™ Technologies) and 0,5% 
Pen-Strep was used per well. Half of the medium was changed every 2-3 days and cells 
inspected visually with light microscopy. 
The iPS-cells were passaged every 3–5 days. Prior to passaging, wells on a new 6-well plate 
were coated with 1:100 Geltrex® in KO-DMEM (Gibco by Life Technologies) for 1 h–
overnight at +37°C.  Passaging was done by treating the iPS-cells with 1 ml Versene® (Lonza) 
per well for 2–5 minutes on a +37°C heating plate, after the removal of differentiated cells. 
When the cells were detaching from the substrate (inspected with light microscopy), Versene® 
was removed and cells scraped into fresh culture medium. Part of the cell suspension was 
transferred onto new Geltrex®-coated wells. Cell attachment was confirmed with light 
microscopy the next day.  
Throughout the experiment, stocks of iPSCs were made by freezing colonies in freezing 
medium (described in chapter 4.3.1). After being frozen down in isopropanol chambers at -
80°C, the cells were stored in liquid nitrogen. 
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4.4 Characterisation of induced pluripotent stem cell lines 
4.4.1 Immunocytochemistry 
Immunocytochemistry for line E1M-E3M was performed at p. 10 and for S1M-S3M at passages 
10,12 and 13, respectively. Immunocytochemistry for line E4G was performed at p. 19. 
Initial washing was done with 1X phosphate-buffered saline (PBS) before fixing for 20 min 
with 4% paraformaldehyde (PFA; Sigma Aldrich) in 1X PBS. After fixing, the cells were either 
stored in 1X PBS at +4°C or stained immediately. Permeabilisation and blocking was 
performed at the same time by 10% normal donkey serum (NDS; Millipore), 0,1% Triton-X 
100 (Sigma Aldrich) and 1% bovine serum albumin (BSA; Sigma Aldrich) in 1X PBS for 45 
min. After blocking, cells were washed once with 1X PBS containing 1% BSA, 1% NDS and 
0,1% Triton-X 100. Incubation with primary antibodies (diluted in previous washing solution) 
included pluripotency markers Sox2 (Sox2 goat IgG; Santa Cruz), Tra 1-60 (Anti-Tra 1–60 
mouse IgM; Millipore) and Tra 1-81 (Anti-Tra 1–81 mouse IgM; Millipore) all diluted 1:200; 
SSEA-4 (SSEA4 mouse IgG; Santa Cruz) diluted 1:100 and Oct3/4 (Anti-human Oct3/4 goat 
IgG; R&D Systems, Inc.) diluted 1:400. Primary antibodies were incubated overnight at +4°C.  
After overnight incubation with primary antibodies, cells were washed three times with 1% 
BSA in 1X PBS, and incubated light-protected with secondary antibodies in 1% BSA in 1X 
PBS for 1 h. The secondary antibodies used at a dilution of 1:800 were Alexa Fluor 568 nm 
donkey anti-goat IgG (Invitrogen) for Oct-3/4 and Sox-2; Alexa Fluor 568 nm goat anti-mouse 
IgG H&L (Invitrogen) for SSEA-4 and Alexa Fluor 568 nm goat anti-mouse IgM M chain 
(Invitrogen) for TRA 1-60 and TRA 1-81. Following incubation, cells were washed twice with 
1X PBS and phosphate buffer (PB) before mounting with Vectashield Mounting Medium 
including 4',6-diamidino-2-phenylindole (DAPI; Vector Laboratories).  
In addition to the pluripotency characterisation, immunocytochemistry for Geltrex®-cultured 
cell line E4G at p. 7 and p. 17 was performed similarly with early neural marker primary 
antibodies Nestin (Anti-Nestin mouse IgG; Millipore) and microtubule-associated protein 
(MAP)-2 (Anti-MAP-2 rabbit IgG; Millipore) at dilutions 1:1000 and 1:400, respectively. 
Secondary antibodies used at a dilution of 1:800 were Alexa Fluor 568 nm goat anti-mouse IgG 
H&L and Alexa Fluor 568 nm goat anti-rabbit IgG, respectively. The samples were stored light-
protected at +4ºC and visualised with Olympus IX51 fluorescence microscope. Images were 
acquired using Olympus DP30BW and edited with DP manager software (Olympus). 
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4.4.2 Expression of pluripotency markers 
4.4.2.1. RNA sample collection, extraction and cDNA synthesis    
All RNA samples were collected using 600 µl of RLT buffer (QIAGEN) containing 10 µl of β-
ME (Sigma Aldrich) per 1 ml of lysis buffer. Before sample collection from feeder-cultured 
iPS-cells, MEF-cells were scraped out into the growth medium under the microscope using a 
pipette tip, leaving the iPS-cell colonies intact. After scraping the growth medium was removed 
and cells were washed twice with 3 ml of 1X PBS.  For feeder-free cultures on Geltrex®, the 
growth medium was removed and cells washed twice with 3 ml of 1X PBS. After washing the 
RLT buffer containing β-ME was added to lyse the cells. Collected samples were stored at -
80°C until RNA extraction. 
RNA extraction was performed using the RNeasy® Mini Kit (QIAGEN) according to the 
manufacturer’s instructions. Additional on-column DNase digestion was performed to digest 
remaining DNA. The purified RNA samples were eluted in 30 µl of sterile H2O. Concentrations 
and purities of the eluted RNA samples were measured spectrophotometrically (NanoDrop 
Spectrophotometer ND-1000). Extracted RNA samples were stored at -80°C. 
RNA samples were reverse transcribed into cDNA by using a High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) according to manufacturer’s instructions. Reaction 
master mix contained 10X RT buffer, 10X RT random primers, 25X dNTP mix (100 mM), 
Multiscribe™ Reverse Transcriptase, RNase inhibitor (Riboblock RNase Inhibitor, Thermo 
Scientific) and nuclease-free H2O in a volume of 10 µl per reaction. A total of 500 ng of 
extracted RNA was used for each reaction, in a volume of 10 µl. Negative –RT controls for all 
samples were also prepared by replacing the Multiscribe™ Reverse Transcriptase with 
nuclease-free H2O, as well as a negative H2O control replacing the RNA in the reaction. The 
cDNA-transcription was carried out with the Thermal Cycler Mastercycler (Eppendorf) and 
reaction conditions were 1) 25°C, 10 min; 2) 37°C, 120 min; 3) 85°C, 5 min and 4) 4°C until 
storage. Synthesised cDNA was stored at -20ºC.  
4.4.2.2 EXO-PCR 
To verify that exogenic plasmid material is no longer present in the iPS-cells, DNA samples 
from episomally transfected cell lines were collected at passage 8. Cells were washed twice 
with 1X PBS before lysis in 80 µl of T1 buffer (Macherey-Nagel). The T1 buffer-lysed samples 
were stored at -70°C until DNA extraction. DNA extraction was performed using Nucleospin® 
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Tissue XS –kit (Macherey-Nagel) according to manufacturer’s instructions. Instead of an 
elution volume of 20 µl suggested in the protocol, a volume of 30 µl of Buffer BE was used. 
Extracted DNA was stored either at -20ºC or -70°C, and the DNA concentrations and purities 
were measured spectrophotometrically (NanoDrop Spectrophotometer ND-1000). Before 
exogenic PCR, all DNA samples were diluted to a final concentration of 25 ng/µl. 
The absence of exogenic plasmid DNA in the electroporated cell lines was assessed by PCR of 
the EBNA-1 gene, which is present in all the transfected plasmids. A pCXWB-EBNA1 plasmid 
dilution series with concentrations of 1 ng/µl–1 fg/µl was used as the positive control and H2O 
as a negative control. Master mixes for each reaction contained 2 µl of Dynazyme buffer, 0.2 
µl of Dynazyme polymerase II (Thermo Scientific), 0.4 µl of 10mM dNTP mix (Fermentas), 
0.4 µl of 25 mM MgCl (Fermentas), 12 µl of RNAse free H2O, 2 µl of both 5 µM EBNA-1 
primers and 1 µl of sample. PCR conditions were 1) 94°C, 2 min; 2) hybridization at 94°C, 30s; 
3) annealing at 60°C, 30s; 4) elongation at 72°C, 30s; and 5) final elongation at 72°C, 5 min; 
6) storing at 4°C until gel electrophoresis. Steps 2–4 were repeated 40X. All genes, primers and 
their annealing temperatures are presented in Table 2. 
Exogenic PCR for Sendai-lines S1M-S3M was done from RNA samples extracted as described 
in chapter 4.4.3. Since cells should be free of viral material at p. 10 (Griesenbach et al., 2005), 
exo-PCR was conducted at later passages 14 and 15. As a positive control, cDNA from an early 
passage (p. 3) of a sendai-transfected line was used. Master mixes were prepared similarly as 
for electroporation lines except for adding 1 µl of DMSO and 50 ng of cDNA per reaction. PCR 
conditions were 1) 94°C, 2 min; 2) hybridisation at 94°C, 30s; 3) annealing at 55°C, 30s; 4) 
elongation at 72°C, 30s; 5) final elongation at 72°C, 5 min; 6) storing at 4°C until gel 
electrophoresis. Steps 2–4 were repeated 40X. All genes, primers and their annealing 
temperatures are presented in Table 2. 
4.4.2.3 ENDO-RT-PCR 
The expression of endogenic pluripotency genes was studied with endo-RT-PCR. RNA sample 
collection was performed from same or closely following passages as for exo-PCR and reverse 
transcribed as described in chapter 4.4.3. Master mixes for endogenic genes glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) (endogenic control), reduced expression (REX)-1, 
OCT3/4 and C-MYC consisted of 2 µl of Dynazyme buffer and 0,2 µl of Dynazyme polymerase 
II (Thermo Scientific), 0,4 µl of 25 mM MgCl (Fermentas), 0,4 µl of 10mM dNTP mix 
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(Fermentas), 2 µl of both 5 µM primers, with 30 ng of cDNA per reaction, adding RNAse-free 
water to a final volume of 20 µl per reaction. For NANOG and SOX2 1 ul of DMSO was added 
per reaction. PCR conditions were 1) 94°C, 2 min; 2) hybridisation at 94°C, 30s; 3) annealing 
at X°C 30s; 4) elongation at 72°C, 30s; and 5) final elongation at 72°C, 5 min; 6) storing at 4°C 
until gel electrophoresis, which was performed as described in chapter 4.4.3. Steps 2–4 were 
repeated 35X. Annealing temperatures X and primers are presented in Table 2. 
Table 2. Genes and their respective primer sequences used for PCR and RT-PCR. All primers 
for both pluripotency and embryoid body germ layer detection are listed in the table. Primers, 
annealing temperatures (Ann. °C) and amplicon sizes in base pairs (bp) are presented. 
Gene Forward primer Reverse primer Size 
(bp) 
Ann. 
(°C) 
GAPDH agccacatcgctcagacacc gtactcagcgccagcatcg 302 60 
sendai exo-OCT4 cccgaaagagaaagcgaacca aatgtatcgaaggtgctcaa 483 55 
sendai exo-SOX2 atgcaccgctacgcagtgagcgc aatgtatcgaaggtgctcaa 451 55 
sendai exo-KLF4 ttcctgcatgccagaggagccc aatgtatcgaaggtgctcaa 410 55 
sendai exo-C-MYC taactgactagcaggcttgtcg tccacatacagtcctggatgatgatg 532 55 
exo-EBNA1 ggggtagaggacgtgaaaga ggtggaaaaatggccttcta 162 60 
endo-OCT4 gacagggggaggggaggagctagg cttccctccaaccagttgccccaaac 144 60 
endo-SOX2 gggaaatgggaggggtgcaaaagagg ttgcgtgagtgtggatgggattggtg 151 60 
endo-REX1 cagatcctaaacagctcgcagaat gcgtacgcaaattaaagtccaga 306 55 
endo-C-MYC gcgtcctgggaagggagatccggagc ttgaggggcatcgtcgcgggaggctg 328 60 
endo-NANOG tgcaaatgtcttctgctgagat gttcaggatgttggagagttc 287 45 
SOX17 cgcacggaatttgaacagta cacacgtcaggatagttgcag 166 55 
SOX1 aaagtcaaaacgaggcgaga aagtgcttggacctgcctta 158 55 
AFP catccaggagagccaagcat cgccacaggccaatagtttg 209 55 
A-cardiac actin ggagttatggtgggtatgggtc agtggtgacaaaggagtagcca 486 55 
PAX6 aacagacacagccctcacaaaca cgggaacttgaactggaactgac 275 55 
VEGFR2 gtgaccaacatggagtcgtg tgcttcacagaagaccatgc 218 55 
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4.4.2.4 Agarose gel electrophoresis 
The PCR-products were run on a 1,7% agarose (peqGOLD Universal Agarose; PeqLab) 
containing 0,01% (V/V) of ethidium bromide (10 mg/ml; Sigma). The products were loaded on 
gel with 6x DNA Loading Dye (Fermentas) using a 50 bp DNA Ladder (Generuler; Fermentas) 
as a molecular weight marker. Loaded samples were run for 50 min at 80 V (BioRad and 
Amersham Biosciences) and gels imaged with UV gel documentation system (UVidoc or 
Chemi XRS Gel Documentation system; Bio-Rad). The images were processed with Adobe 
photoshop CC 2017. 
4.4.3 Karyotyping 
Before collecting DNA samples for karyotyping, each MEF-co-cultured cell line was grown 
for two passages on feeder-free Geltrex®-surfaces prepared as described in chapter 4.3.2. 
Samples were collected as described in chapter 4.4.2.2 at p. 12 from lines E1.1M-E3.2M; p. 18 
from line S3M; p. 15 from lines S1M and S2M and at p. 14 for E4G. The extracted DNA 
samples were sent to the Finnish Microarray and Sequencing Centre for karyotyping with 
KaryoLite BoBs (Product number 4501–0010, Perkin Elmer) (For a more detailed description 
of the karyotyping method, see Lund et al. 2012). 
4.4.4 Embryoid body formation assay 
iPS-cell lines E1.2M, E2.1M E3.2M and S2M at p. 17 and 18 were used for the EB formation 
assay. EB differentiation of the iPS-cell lines was done using floating culture on non-adhesive 
12-well plates (MPC treatment; Thermo Fisher Scientific). MEF-layers were removed and 
remaining iPS-cell colonies scraped into KSR-medium lacking β-FGF and transferred onto the 
non-adhesive 12-well plates. The cells were cultured at 36,5°C   and 5% CO2 for 6 weeks. 
Medium for the cells was changed at day 6 followed by medium change every 2-3 days. 
The differentiation status of the formed EBs was assessed by RT-PCR of two genes for each 
germ layer. For the ectoderm SOX1 and Paired box gene 6 (PAX6); for the mesoderm α-cardiac 
actinin and vascular endothelial growth factor receptor 2 (VEGFR2) and for the endoderm 
SOX17 and α-fetoprotein (AFP) were studied (Table 2).  
EBs from three wells were combined, washed with 1X PBS before lysis in RLT buffer 
containing β-ME. RNA extraction and cDNA synthesis was performed as described in chapter 
4.4.3. The master mixes and PCR reactions were similar as for NANOG and SOX2 in chapter 
4.4.5, using 50 ng of cDNA with an annealing temperature of 55°C. Steps 2)-4) were repeated 
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40X. Housekeeping gene GAPDH was used as and endogenic control and H2O and –RT 
samples as negative controls.  
4.5 Real-time-qPCR 
To study the expression of pluripotency genes at an early and later passage, and between 
different patients, a Taqman-chemistry based real-time quantitative PCR experiment was 
carried out. cDNA-samples from all MEF-grown, episomally transfected lines E1.1M-E3.2M 
at passages 3 and 9 (except for line E2.4M at p. 9) were synthesised as described in chapter 
4.4.2.1, and studied to detect the expression of pluripotency genes OCT3/4, NANOG, C-MYC 
and KLF4. GAPDH was used as an endogenic control and –RT samples and H2O as negative 
controls.  
The PCR master mixes consisted of 7,5 µl of Taqman universal Master mix (2x) (Applied 
Biosystems), 0,75 µl of gene expression assay (Applied Biosystems) (see Table 3) and 1 µl of 
cDNA with H2O added to a final volume of 15 µl per reaction. All samples were prepared as 
triplicates. PCR reaction was carried out with the 7300 Real-time PCR system (Applied 
Biosystems) and PCR conditions were 1) 50°C, 2 min; 2) 95°C, 10 min; 3) 95°C and 4) 60°C 
1 min, repeating steps 3) and 4) 40 cycles. Ct values were determined using 7300 SDS Software 
(Applied Biosystems) and relative quantification was calculated in MS Excel 2016 using the 2-
∆∆CT method (Livak and Schmittgen, 2001) using equation 1: 
∆∆𝐶𝑡 = 2
−[(𝐶𝑡,𝑔𝑒𝑛𝑒−𝐶𝑡,𝐺𝐴𝑃𝐷𝐻)−(𝐶𝑡,𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑜𝑟(𝑎𝑣𝑔)−𝐶𝑡,𝐺𝐴𝑃𝐷𝐻(𝑎𝑣𝑔))]  (1) 
Statistical analyses were performed with IBM SPSS Statistics 23. The level of statistical 
significance for all statistical analyses was set to <0.05 (p-value). Because of the relatively 
small sample size, and the observed skewness and data histogram, a normal distribution of the 
data could not be assumed for any comparisons, hence only non-parametrical statistical tests 
were used.  
First, the gene expression data was normalised against the housekeeping gene GAPDH and 
gene expression of all studied lines at p.9 was compared against all lines at p. 3. To test if there 
are any statistically significant differences in the relative gene expressions between the two 
passages, a non-parametric Mann-Whitney U test was used. 
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Table 3. Gene expression assay IDs used for real-time-qPCR 
Gene Gene expression assay ID 
GAPDH Hs02786624_g1 
SOX2 Hs00999632_g1 
NANOG Hs02387400_g1 
KLF-4 Hs00358836_m1 
C-MYC Hs00153408_m1 
 
Secondly, the differences in gene expression at p.3 and p. 9 for each patient was studied. To do 
this, data from all lines for each patient was normalised against GAPDH and expression at p.9 
was compared to the expression for the same lines at p. 3. The differences in relative gene 
expressions at different passages was compared using a Mann-Whitney U test. Since there was 
only two lines in both groups for patient 3, statistical tests were not performed for this patient. 
Finally, the expression between patients at the same passage was also studied. Lines were 
normalised against GAPDH and compared to lines form patient 1 at p.3 and p. 9, respectively. 
A Kruskal-Wallis analysis was performed to detect statistically significant differences between 
patients at the same passage. 
4.6 Cardiac differentiation 
4.6.1 Cardiac differentiation and culture conditions 
For cardiac differentiation two lines from the same patient but reprogrammed with different 
method were chosen for comparison: E2.1M and S3M both at passage 18. Differentiation was 
performed in co-culture with mouse endoderm-like cells (END2-cells), cultured in END2-
medium (DMEM/F-12 (Gibco by Life Technologies) supplemented with 7,5% FBS (Gibco by 
Life Technologies), 1% NEAA (100x MEM; Gibco by Life Technologies), 2 mM L-glutamine 
(GlutaMAX™, Life Technologies) and 0,5% Pen-Strep (Sigma Aldrich)) (Mummery et al. 
2003).  
Before the differentiation, END2-cells were treated with 5μl/ml Mitomycin C (R&D Systems) 
for 3h at +37°C to prevent mitosis. After the mitomycin C -treatment, cells were counted and 
re-plated at a density of 175 000 cells/well sterile 12-well plates. Before plating, the wells were 
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treated with 0,1% gelatin as described in chapter 4.3.1. Cell attachment was verified by light 
microscopy the next day. 
Next, medium for the END2-cells was changed into 0% KO-SR hES medium (KO-DMEM 
(Gibco by Life Technologies) supplemented with 2.92 mg/ml AA (Takahashi et al., 2003; 
Sigma Aldrich), 2 mM L-glutamine (GlutaMAX™, Life Technologies), 1% NEAA (100x 
MEM; Gibco by Life Technologies), 0,5% Pen-Strep (Sigma Aldrich) and 0.1 mM β-ME 
(Sigma Aldrich)). MEF layer was removed from the iPS-cells, and iPS-colonies transferred 
onto the END2-cells plated the day before. The number of iPS colonies transferred per well 
was approximately 40 for line S2M and 52 for line E2.1M. Medium was changed on days 7, 9 
and 14. On day 16 the medium was changed into 10% KO-SR hES without AA. After this 
medium was changed every 2–3 days. Cells were cultured at +37°C and 5% CO2. Cells were 
visualized under the light microscope every 1–3 days to observe appearing differentiated, 
beating areas. When no new beating areas had appeared for over 7 days, the beating 
cardiomyocyte areas were dissociated for further characterization. 
4.6.2 Dissociation protocol for beating areas 
On day 30 after beginning the differentiation, three beating areas from each cell line was 
dissected and processed into single-cell suspension before spinning onto small glass plates. The 
dissociation protocol was performed by the lab technician. Briefly, beating areas were dissected 
using a microscalpel and washed with low calcium buffer for 30 minutes at room temperature 
(RT). Then the cells were dissociated into single cells by treating them with collagenase A 
(Roche Diagnostics) for 45 minutes at +37°C. After this cells were transferred into KB medium 
with a high K+-concentration for 1 hour at room temperature. After this the cells were 
centrifuged and re-suspended in a volume of 150 µl of hES-medium. This single cell suspension 
was spinned down on a small glass cover slip with the cytospin centrifuge for 5min at a speed 
of 600 rpm. 
4.6.3 Immunocytochemistry  
Immunocytochemistry for the cytospinned cells was performed as described in chapter 4.4.1. 
The primary antibody used was a cardiac specific marker Troponin T (goat cardiac Troponin T 
IgG; Abcam) at a dilution of 1:2000 and the secondary antibody Alexa Fluor 568 nm (donkey 
anti-goat IgG (Invitrogen)).  
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4.6.4 Evaluation of cardiac efficiency 
The efficiency of the cardiac differentiation of the two lines was assessed in two ways. Firstly, 
the number of beating areas prior to dissociation was divided by the total number of 
differentiated colonies. Secondly, efficiency was assessed from the immunocytochemistry of 
the cardiac cells.  from four randomly acquired immunofluorescence images from both lines by 
dividing the number of cardiac-specific antibody Troponin T- positive cells with the total cell 
count (stained by DAPI). Images were acquired using Olympus DP30BW and edited with DP 
manager software (Olympus). 
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5. Results 
5.1 Characterisation of iPS-cell lines 
After establishment and maintenance in culture for several passages, all iPSC-lines were 
characterised to assess their pluripotency and quality. Characterisation of the iPSCs is 
performed during the stabilisation phase of reprogramming (David and Polo, 2014). All 
characterisations in this study were performed between passages 7-17. The expression of 
exogenic genetic material was studied for episomally derived lines by PCR, and by RT-PCR 
for the sendai-virally reprogrammed lines. The expression of endogenic pluripotency genes was 
assessed by RT-PCR. An EB formation assay in floating culture (Itskovitz-Eldor et al., 2000; 
Takahashi et al, 2007) was performed to assess in vitro -differentiation potential. The presence 
of the germ layers was then confirmed by RT-PCR for two genes of each derm (endoderm, 
mesoderm, ectoderm). Karyotyping analysis was performed in Turku in the Finnish Microarray 
and Sequencing Centre. However, not all studied lines were characterised with these methods. 
Characterisations of all lines included assessment of the absence of exogenic genetic material, 
and the study of expression of the endogenous pluripotency genes. Karyotyping was also 
performed for all lines. Other characterisations were performed for only chosen lines described 
in the materials and methods -section. Also notable, no characterisation of Geltrex®-established 
line E5G was performed, since the line was lost due to complete differentiation at p. 9. 
Pluripotency gene expression was also studied with real-time-qPCR. 
5.1.1 Morphology 
The iPS-cells grew in typical dense, flat colonies surrounded by MEF-cells throughout the 
experiment. Also a typical high nucleus to cytoplasm -ratio with large nucleoli could be 
observed.  
The iPS-cells formed round-shaped colonies of even color, sometimes with darkened, 
differentiated material around the edges of the colonies. The degree of differentiated material 
around the colonies was quite small. However, as reaching higher passage numbers, also a 
higher degree (although altogether a small degree) of differentiated material was observed. 
Since all MEF-co-cultured iPSC-lines established a similar kind of morphology throughout the 
experiment, representative images from only four different lines at various passages are 
presented in Figure 6.  
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Figure 6. MEF-co-cultured iPS-cell morphologies at different passages. A) Line E1.2M at p. 
1. A clear, round colony is already visible, but a lot of differentiated material is visible around 
the edges of the colony. B) Line E2.1M at p. 8. Two colonies grown together can be seen on 
the right. The colonies have a dense and clear structure and are surrounded by MEF-feeder 
cells. C) Line E1.4M at p. 14. Three individual colonies can be seen with a little differentiated 
material around the edges. D) Line E3.2M at p.18. Even at the end of the experiment, the lines 
were able to elicit a nice morphology with little or no differentiated material around the edges. 
Colonies are round, flat and even-colored.  
5.1.2 PCR and RT-PCR 
The absence of exogenic genetic material was confirmed by PCR for electroporated lines and 
RT-PCR for sendai-lines. For electroporated lines the expression of EBNA-1 gene (present in 
all the transfection plasmids), and for the sendai-lines of all viral transgenes KLF-4, SOX-2, C-
MYC and OCT-3/4 was studied. The positive EBNA-1 plasmid dilution series could amplify 
the studied sequence from down to 1 pg of plasmid, but not from any of the studied iPS-lines 
(see Figure 7A). The sendai positive control (RNA from  a sendai-line at p. 3) was also able to 
amplify all the viral transgene sequences, but no viral sequences were detected in the iPS-lines 
(Figure 7B). 
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Figure 7. PCR and RT-PCR to detect exogenic genetic material in iPSC-lines. A) PCR for the 
EBNA-1 gene included in the transfection plasmid in electroporated lines showed that no 
exogenic material was present in iPS-lines at p. 8. NC=negative control (H2O instead of RNA 
in the reaction), and as the positive control an EBNA-1 plasmid dilution series. B) RT-PCR for 
viral transgene sequences for KLF-4, SOX-2, C-MYC and OCT-3/4 revealed no viral exogenic 
material at p. 14 and 15. PTC=positive template control, a sample collected from p. 3 sendai-
transfected line; NC= negative control (a negative -RT control with no reverse transcriptase in 
the cDNA turn). 50 bp DNA ladder. 
After verification of the absence of exogenic genetic material, the expression of endogenic 
pluripotency genes REX1, OCT-3/4, C-MYC, NANOG and SOX-2 was studied at mRNA level 
by RT-PCR. GAPDH was used as an endogenic control, and negative –RT control (with no 
reverse transcriptase in the cDNA-turn) or H2O control (with H2O instead of RNA in the 
reaction) for all samples were also studied. All studied iPSC-lines showed endogenic expression 
of all studied pluripotency genes, except C-MYC for line E2.4M (Figure 8).  However, a rerun 
with double the amount of cDNA was able to amplify the gene also for line E2.4M (results not 
shown). No apparent differences in the expression of pluripotency genes in the sendai-
reprogrammed lines compared to electroporation-lines were visible. 
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Figure 8. RT-PCR for studying the expression of endogenic pluripotency genes. GAPDH was 
used as an endogenic control, and a –RT control PCR (with no reverse transcriptase in the 
cDNA turn) with GAPDH was also conducted. All studied genes REX-1, NANOG, SOX-2, C-
MYC and OCT-3/4 were expressed in all lines except C-MYC in E2.4M. Expression of SOX-
2 and C-MYC was generally lower than the expression of other genes. NC=negative control (a 
negative -RT control with no reverse transcriptase in the cDNA turn). 50 bp DNA ladder. 
5.1.3 Immunocytochemistry 
The expression of pluripotency factors Sox-2, Oct-4, Ssea-4, Tra 1-60 and Tra 1-81 was studied 
at protein level with immunocytochemistry using DAPI as a counterstain. As seen in Figure 9, 
line E2.1M stained positive for all studied pluripotency factors. Other studied iPSC-lines 
(E1.2M, E3.2M and S1M-S3M) also expressed pluripotency proteins in a similar manner. No 
apparent difference in protein expression between the lines was visible, thus results for only 
one representative line are shown. The results for other lines can be found in Appendix B. 
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Figure 9. Protein expression of pluripotency markers in iPSC-line E2.1M at p. 10 studied with 
immunocytochemistry. All used markers Sox-2, Oct-4, SSEA-4, TRA 1-60 and TRA 1-81 
stained positive (red). DAPI counterstain was used to stain nuclei (blue) from both iPS- and 
MEF-cells (stained only blue in the Merge photos). 
5.1.4 Karyotyping 
DNA samples from all MEF-co-cultured iPS-lines were sent to the Finnish Microarray and 
Sequencing Centre in Turku for karyotyping. All lines possessed a normal karyotype with no 
large chromosomal aberrations (data shown only for E4G in chapter 5.2.2). 
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5.1.5 Embryoid body formation 
To assess the in vitro –differentiation potential of the iPS-cells, an EB-formation assay was 
performed for lines E1.2M; E2.1M; E3.2M and S2M. The EBs grown for 6 weeks in floating 
culture formed cell aggregates of varying sizes with typical pigmented areas (Figure 10A). The 
differentiation into all three germ layers (endoderm, mesoderm and ectoderm) was studied by 
the expression of two genes for each derm (Figure 10B). Only for line S2M the expression of 
all studied genes was detected. Electroporation lines showed no gene expression for 
mesodermal gene α-cardiac actinin or ectodermal SOX1. Also a second RT-PCR using double 
the amount of cDNA failed to amplify these genes. Other genes were amplified, and at least 
one gene for each derm was expressed for all lines. The endogenous control gene GAPDH was 
amplified in all lines (data not shown). 
 
Figure 10. Formation of embryoid bodies and detection of the three germ layers by RT-PCR. 
A) Light microscopy images of embryoid bodies grown for 6 weeks in floating cultures. Line 
E2.1M on the left and E1.2M on the right, both showed typical pigmented areas in some of the 
various sized EBs. B) RT-PCR for lines E1.2M; E2.1M; E3.2M and S2M for endodermal genes 
AFP and SOX17, mesodermal genes α-cardiac actinin and VEGFR2 and ectodermal genes 
SOX1 and PAX6. Not all genes were expressed in all lines except for line S2M, but at least one 
germ for each germ layer was detected for all. NC=negative control (a negative -RT control 
with no reverse transcriptase in the cDNA turn). 50 bp DNA ladder. 
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5.1.6 Quantitative pluripotency gene expression 
The relative gene expression was studied by real-time qPCR for pluripotency genes SOX2, C-
MYC, NANOG and KLF4. The raw Ct values obtained from the measurements are presented 
in Appendix C.  
The relative expression of all genes at p.9 compared to p. 3 for all studied cell lines combined 
is presented in Figure 11. The expression of SOX2, C-MYC and KLF4 was fairly similar at 
both passages, and no statistically significant differences were observed.  NANOG expression 
at p.9 was statistically significantly lower compared to p.3 (p-value = 0.004, Figure 11) when 
looking at all lines combined.  
Since multiple lines form each patient were studied, the pluripotency gene expression for each 
patient at passages 9 and 3 was compared. Due to small sample size, data for patient 3 was not 
analysed. The results for patients 1 and 2 are presented in Figure 12.  NANOG expression for 
patient 1 was statistically significantly decreased at p. 9 compared to p.3 (p-value = 0.043; 
Figure 12A), as well as SOX2 expression for patient 2 (p-value = 0.034; Figure 12B). 
Statistically significant differences for other studied pluripotency genes were not observed for 
either patient. 
No statistically significant differences were observed in pluripotency gene expression between 
patients at the same passage. 
 
Figure 11. The relative gene expressions of pluripotency genes KLF4, C-MYC, SOX2 and 
NANOG at passages 3 (p. 3) and 9 (p. 9), assessed by real-time-qPCR. Overall fold changes 
are small for all genes. No apparent differences in the relative gene expressions can be observed, 
except for NANOG. Analysed by a non-parametric Mann-Whitney U test the relative 
expression of NANOG is significantly higher at p. 3 than at the later p. 9. Data is normalised to 
GAPDH and compared to all lines at p. 3; mean ± SD (standard deviation); N=10 at p.3 and 9 
at p.9; * p < 0.05. 
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Figure 12. The relative gene expressions of pluripotency genes KLF4, C-MYC, SOX2 and 
NANOG for patients 1 and 2 assessed by real-time-qPCR. A) Relative gene expressions of each 
gene at passage 3 (p.3) and passage 9 (p. 9) for patient 1. Differences in gene expression 
between the two passages was studied with a Mann- Whitney U test, and revealed a statistically 
significant decrease in NANOG expression at p. 9. Data is normalised to GAPDH and compared 
to all p. 3 lines from patient 1; mean ± SD (standard deviation); N=4; * p < 0.05. B) Relative 
gene expressions of each gene at p.3 and p. 9 for patient 2. A Mann-Whitney U test revealed a 
statistically significant decrease in SOX2 expression at p.9. Data is normalised to GAPDH and 
compared to all p. 3 lines from patient 2; mean ± SD; N=4; * p < 0.05. 
5.2 Feeder-free experiment 
5.2.1 Morphology and growth 
The morphologies of the Geltrex®-cultured lines were somewhat different from traditional 
MEF-co-cultured iPSC-lines. The morphologies of the individual colonies often tended not to 
be completely round but had partly sharp edges (see Figure 13A), as frequently encountered 
with feeder-free monolayer cultures (Brouwer et al., 2016). However, also nice, round colonies 
could be seen (Figure 13B).  Also some kind of differentiated cell mass between iPSC-colonies 
was visible at almost every passage in both lines (Figure 13C). Passaging this cell mass further 
resulted in early neural network-resembling structures (Figure 13D). To preserve nice, even 
colonies of iPS-cells, Geltrex®-cultured lines required scraping off differentiated cell mass 
before passaging. Line E4G was also passaged at one point by picking only a part of a good-
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looking colony with a pipette tip, thus passaging only that further. Even so, at every passage 
differentiated cell mass (similar to that in Figure 13C) reappeared. Without removal, the 
amount of differentiated cell mass seemed to increase, and eventually line E4G ended up in a 
morphology similar to that represented in Figure 13D and was lost due to complete 
differentiation at p. 9. Compared to the MEF-cultured lines, the feeder-free lines had a more 
rapid growth rate and had to be passaged twice as often as the MEF-cultured lines. 
 
Figure 13. Typical morphologies of the Geltrex®-cultured lines. A) Line E4G at p. 14. The 
iPS-cells formed dense colonies with even color, but with more sharp edges than in lines grown 
in co-culture with MEF-cells. B) Line E5G at p. 1. The Geltrex®-cultured lines were able to 
form dense, even, round-shaped colonies after picking. C) Line E4G at p.6. In between iPS-
colonies a differentiated cell mass is visible. Differentiated cells in various amounts appeared 
at  almost all passages in both Geltrex®-cultured lines. D) Line E4G at p. 7. Differentiated cell 
mass passaged further has formed a single, neural-cell-resembling web. No iPSC-colonies are 
present. Also line E4G was lost at p.9 due to differentiation into cells of similar morphology. 
Scale bar 1000 µm. 
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The cells seen in Figure 13D and later at p. 17 were stained immunocytochemically with early 
neural markers Nestin and MAP-2.  Both markers stained positive (Figure 14, B and C), 
indicating neural differentiation of the iPS-cells. The differentiated cells that had been passaged 
on further to develop the morphology seen at. p 7 (Figure 14A) formed thin, tubular-like 
filamentous structures when immunocytochemically stained with early neural marker Nestin. 
All cells in the well stained positive. Interestingly, another staining with Nestin at p. 17 for the 
less matured differentiated cell mass among the iPSC-colonies, showed no tubular structures or 
denser cell areas. Moreover, also iPSC-colonies not expressing Nestin were observed. Colonies 
not expressing MAP-2 were also seen, indicating that only a part of the iPSCs have 
differentiated into early neural progenitors. 
 
Figure 14. Immunocytochemistry for Geltrex®-line E4G using early neural markers MAP-2 
and Nestin (red) and DAPI as a counterstain (blue). Also light microscopy images of the stained 
cells are presented. A) Nestin stained positive at p. 7. Thin, filamentous structures are visible, 
with denser cell areas. All cells stained positive for Nestin. B) Cells stained positive for Nestin 
also at p. 17 but no filamentous structures nor denser cell areas are visible. iPS-colonies with 
no neural differentiation were also visible (only stained blue in the Merge-photo) C) The iPSCs 
stained positive also for MAP-2 at p. 17.  
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5.2.2 Characterisation 
Immunocytochemistry for line E4G revealed expression of the pluripotency proteins (Figure 
15), Line E4G was also characterised by PCR of the EBNA-1 gene to verify the absence of 
exogenous transfection plasmid DNA material, RT-PCR of endogenous pluripotency genes, by 
immunocytochemistry of pluripotency markers and by karyotyping. All endogenous genes were 
expressed at mRNA-level in the cell line (Figure 16A), and no exogenous genetic material was 
detected (Figure 16B). Karyotype analysis performed at the Finnish Microarray and 
Sequencing Centre revealed a normal karyotype. The karyotyping results can be found in 
Appendix D. 
 
Figure 15. Immunocytochemistry for pluripotency markers Sox-2, Oct-4, Ssea-4, Tra 1-60 and 
1-81 for line E4G. The cell line stained positive for all studied proteins (red). DAPI was used 
as a counterstain. Merge-photos are shown on the right with a scale bar of 50 µm. 
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Figure 16. Characterisation of Geltrex®-line E4G. A) RT-PCR for endogenous pluripotency 
genes REX-1, NANOG, SOX-2, C-MYC and OCT-3/4 and an endogenic GAPDH control. All 
endogenous genes were expressed. NC= negative control, -RT control (a negative- RT control 
with no reverse transcriptase in the cDNA turn). B) PCR for the EBNA-1 gene using an EBNA-
1 plasmid dilution series as a positive control. Nothing amplified from line E4G even though 
DNA from 10pg of plasmid gave a clear band. NC=negative control (a negative control with 
no DNA polymerase in the reaction). 50 bp DNA ladder. 
5.3 Reprogramming efficiency 
iPS-reprogramming efficiency was studied for episomal lines from patients 1-5. The efficiency 
was assessed in two ways: after transfection, all appearing colonies were counted and divided 
by the number of cells used for transfection, as well as by dividing the number of colonies that 
survived after picking with the number of colonies picked. Efficiencies are presented as 
percentages. Results are shown in Table 4.  
Table 4. Reprogramming efficiency for electroporation lines generated from patients 1-5.  
  Transfected 
Cells 
Colonies  Efficiency 
% 
Picked 
Colonies  
Successful 
Colonies 
Efficiency 
% 
Patient 1 600 000 96 0.016 35 20 57.1 
Patient 2 600 000 31 0.005 13 9 69.2 
Patient 3 600 000 100 0.017 24 13 54.1 
Patient 4 500 000 8 0.002 7 4 57.1 
Patient 5 500 000 21 0.004 14 11 78.5 
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Transfection efficiencies remained very low, in the range of 0,005–0,017% for all lines, 
assessed by the number of colonies that appeared after transduction of the reprogramming 
factors. The survival rates of picked colonies was much higher, but no notable differences 
between the Geltrex®-established or MEF-established lines could be seen. Variability between 
patients was as big as variability between the two establishment methods. No statistical analysis 
was performed because of the small sample size. 
5.4 Cardiac differentiation and efficiency 
Cardiac differentiation was performed for lines E2.1M and S2M. The cardiac differentiation 
was assessed by visually inspecting beating areas in co-cultures with END2-cells and by 
immunocytochemistry of three dissected and dissociated beating areas with cardiac-specific 
protein Troponin T (Figure 17). The first beating areas appeared on days 9 (S2M) and 8 
(E2.1M) of the differentiation protocol. Beating areas may still appear even at day 30 of the 
differentiation protocol but since no new beating areas had appeared for over 7 days at day 30, 
the beating areas were dissected, spinned down on glass cover slips and stained with a cardiac-
specific marker Troponin T.  
 
Figure 17. Cardiac differentiation and efficiency assessed by immunocytochemistry with 
cardiac-specific Troponin T. Four images acquired randomly from both lines and the ratio of 
cardiac Troponin T –positive cells (red) to total cell count (nuclei stained blue by DAPI) was 
used to assess the differentiation efficiency. Efficiency was also calculated as the ratio of 
beating areas appearing in the END-2 co-cultures to total number of colonies transfected. One 
image for both cell lines is shown. A) Cardiac Troponin T- staining for line E2.1M. B) Cardiac 
Troponin T- staining for line S2M. 
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The differentiation efficiency between the two lines was assessed in two ways. Firstly, by 
comparing the number of beating areas divided by the number of iPSC-colonies used for 
differentiation (see Table 5), and secondly by immunocytochemical methods. Four images from 
both Troponin T-labeled lines were taken randomly, and the Troponin T-positive cell count was 
divided by total cell count (given by counterstaining with DAPI). The results are shown in Table 
5. Overall, differentiation efficiency by the number of beating areas remained quite low, 2.5% 
and 4.6%. The efficiency of the sendai-line S2M, however, was almost twice as high as for the 
episomal line E2.1M.  Also by the amount of Troponin T -positive cells the sendai-line was 
superior, although the difference was not as big as with the beating area count. In conclusion, 
assessed by both methods, the sendai-line S2M differentiated more efficiently compared to the 
electroporation line E2.1M from the same patient. 
Table 5. Cardiac differentiation and efficiency. The beating areas formed during the 
differentiation and the number of iPSC-colonies originally used for differentiation. Efficiency1 
is calculated as their ratio. From the immunocytochemistry, the Troponin T –positive cells and 
the total amount of cells were counted, and the efficiency calculated as their ratio. Efficiencies 
are presented as percentages.  
  
Colonies 
 
Beating 
areas  
 
Efficiency 
% 
Total cell count Troponin T -
positive cells 
Efficiency 
% 
E2.1M 588 15 2.5 55 29 52.7 
S2M 241 11 4.6 89 60 67.4 
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6. Discussion 
6.1 iPSC-generation efficiency 
The differentiation efficiencies in this study were compared between MEF- and, and Geltrex®-
established lines. Although in the original paper by Okita et al. reprogramming by episomal 
plasmids was enhanced by 10-100-fold by the addition of p53 suppressor (Okita et al., 2011), 
with efficiencies of approximately 0,03% or higher, the use of the same reprogramming method 
in this study resulted in modest reprogramming efficiencies in the range of 0,005–0,017% 
(Table 4). However, it was possible to generate iPSC-lines by this method from all patients 
even in feeder-free conditions. Although viral methods are usually considered more efficient 
(Brouwer et al., 2016), the lower reprogramming efficiencies are not as important as the 
generation of higher-quality, integration-free iPSCs with no risk of insertional mutagenesis or 
transgene reactivation.  
The efficiency of reprogramming was assessed both by the number of colonies appearing after 
transduction as well as the number of colonies surviving after the first picking. Neither of these 
methods revealed any trends in reprogramming efficiency between the Geltrex®- and MEF-
cultures lines. The highest and lowest efficiencies by colony number were obtained for MEF-
lines, and no meaningful differences in the efficiencies on colony survival between the two 
culturing methods were observed, suggesting that variability in the genetic or epigenetic 
profiles between patients affects the reprogramming method more than the culture conditions 
used in this study. 
6.2 Pluripotency of iPSC-lines 
The generation of integration-free iPSC-lines with no detectable trace of the ectopic expression 
is important for the generation of high-quality iPSC-lines. Integrating methods can result in 
insertional mutagenesis hampering the normal function of the cells (Brouwer et al., 2016). 
Moreover, if reprogramming factors persist in the iPS-cells even after differentiation, the 
reactivation of these transgenes can result in de-differentiation and tumorigenic formation 
(Okita et al., 2007), which is problematic especially when considering the clinical use of iPSCs. 
Although considered as a non-integrating method, iPSC-lines generated by plasmid 
transduction have been reported to integrate into the host cell genome (Montserrat et al., 2011). 
Moreover, Yu et al. generated lines using a single transduction of three oriP/EBNA-1 plasmids 
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containing OCT4, SOX2, NANOGg, KLF4; OCT4, SOX2, SV40 large T antigen; and C-MYC 
and LIN28 and reported that only 1/3 of the subclones lost the episomal plasmids (Yu et al., 
2007). However, more recent studies also show successful loss of plasmid during extended 
periods of culturing. Hu et al. reported plasmid-free lines at p. 15 (Hu et al., 2011), as Chou et 
al. reported similar results at p. 15 (Chou et al., 2011).  In line with these results, no plasmid 
DNA could be detected by PCR of the EBNA-1 gene in this study. All generated, MEF-cultured 
iPSC-lines were transgene-free already at p. 8. Furthermore, also the Geltrex®-cultured line 
E4G failed to amplify DNA of the EBNA-1 gene (Figure 16B), indicating the loss of the 
reprogramming plasmids.   
In addition to the episomal plasmid reprogramming method, also the sendai-viral transfection 
of the reprogramming factors as negative-sense single-stranded RNA is considered an 
integration-free method. The viral RNA will not enter the nucleus and will usually be diluted 
out of the cells by p. 10 after the infection (Malik and Rao, 2013). Studied by RT-PCR at p. 14 
and 15, the sendai-virally reprogrammed iPSC-lines also failed to amplify sequences for any of 
the viral transgenes in this study (See Figure 7B). Thus, all characterised lines studied were 
free of ectopic reprogramming factors, independent of the generation method or culturing 
conditions.  
After verification of the absence of ectopic reprogramming factors, the expression of 
endogenous pluripotency genes REX1, NANOG, SOX2, C-MYC and OCT4 was studied by 
RT-PCR. All the studied iPSC-lines expressed all studied pluripotency genes (see Figures 8 
and 16A), indicating successful reprogramming. Furthermore, immunocytochemical staining 
of pluripotency-related surface antigens SSEA-4, tumor-related antigen (TRA)-1-60 and TRA-
1-81 and pluripotency-related proteins Oct3/4 and Sox2 were positive for all studied lines. 
Thus, in addition to being transcribed, the mRNAs of pluripotency genes are also being 
translated into protein. The protein expression assessed by the immunocytochemical staining 
appeared similar in the episomal and sendai lines studied.  
Genomic instability in pluripotent stem cells has been detected in ESCs since the early 2000, 
and is also a major concern in iPSC-lines (Ruiz and Fernandez-Capetillo, 2015). The forced 
expression of transcription factors required for reprogramming has been linked to an 
accumulation of various genomic aberrancies such as whole-chromosome aneuploidies, sub-
chromosomal deletions or amplifications, point mutations and copy number variants. The 
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mechanisms causing the genomic instability remain largely unknown (Ruiz and Fernandez-
Capetillo, 2015). Since the accumulation of different genomic aberrations may alter cell 
behavior, they could dramatically distort experimental results and thus affect scientific 
conclusions (Weissman et al., 2001). To verify that no large chromosomal aberrations are 
present in the generated iPSC-lines, DNA samples from each line were sent to the Finnish 
Microarray and Sequencing Centre in Turku for karyotyping. Although all lines expressed a 
normal karyotype, the absence of smaller genetic aberrations cannot be verified by this method. 
iPSCs should be able to spontaneously differentiate into all three germ layers (endoderm, 
mesoderm and ectoderm) when grown in suspension culture (Itskovitz-Eldor et al., 2000; 
Takahashi et al., 2007). The presence of all the three dermal layers was studied by RT-PCR 
using two genes for each derm. Three episomally derived lines and one sendai-line were 
characterised. While the sendai-virally generated line was expressed all studied genes, the 
episomal lines expressed only some of the studied genes (See Figure 10). However, expression 
of at least one gene for each derm was detected, indicating that also these lines could 
differentiate into all three germ layers. In addition to the characterisation of this in vitro -
differentiation potential, further characterisation of the in vivo -differentiation potential could 
be performed by a teratoma assay in immunodeficient mice. 
6.3 Maintenance of pluripotency in culture 
The most important thing for the PSC culture conditions is to maintain the undifferentiated, 
pluripotent state of the stem cells. While traditional culture methods relying on serum- or 
knock-out serum conditions and MEF-cells usually work comparatively well in maintaining the 
undifferentiated state of the PSCs, they possess two key problems. In addition to the feeder 
cells of mouse origin, also the media usually include xenogenic components. Moreover, the 
factors secreted from MEF-cells to maintain the pluripotency, as well as factors in serum-
containing medium are not fully defined. Being able to establish GMP-standardised culture 
conditions for PSCs requires fully defined conditions. In addition, the xeno-free culture 
conditions are of importance especially if planning therapeutic use of the iPSCs.  
Numerous different studies report successful maintenance of pluripotent stem cells in feeder-
free culture conditions using Matrigel and mTeSR1 medium (Akopian et al., 2010; Hakala et 
al., 2009; Ludwig et al., 2006). Geltrex® is very similar to Matrigel, and both are secreted 
extracellular matrix proteins purified from murine Engelbreth-Holm-Swarm (EHS) tumor cells. 
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While Geltrex®-cultured line E4G used in this study expressed pluripotency markers similarly 
as MEF-cultured lines at mRNA and protein level (Figures 15 and 16A), indicating that iPSCs 
could be generated and maintained in culture for extended periods, it is also noteworthy that a 
higher degree of differentiated cells was present at all passages when compared to MEF-
cultured lines. Moreover, the other Geltrex®-cultured line E5G was completely lost due to 
differentiation at p. 9. At p. 7 and 17, line E4G stained positive for early neural markers MAP-
2 and Nestin. Based on the similar morphology of the cells, also line E5G would most probably 
have stained positive for these markers (Figure 14). These results suggest that culturing in 
feeder-free conditions using Geltrex® and mTeSR1 medium leads to a high degree of 
differentiated cells of the neural lineage. Upon culturing these cells further for a few passages, 
they mature forming a tubular network not visible at less mature cells still expressing Nestin 
and MAP-2. Since Nestin is an intermediate filament present in early neural progenitors but 
ultimately lost upon complete differentiation into a certain neural cell type, the presence of 
Nestin in the more matured cells can indicate two things. Either the progenitors could have 
terminally differentiated into neural subtypes in prolonged culture, or the culturing conditions 
used support the differentiation into early neural progenitor but suppresses further commitment 
of these cells.  
The neural differentiation observed in this study is in line with the findings of Ojala et al. (Ojala 
et al., 2012). Upon long-term culture of five hIPSC-lines, they also encountered more 
differentiation in the feeder-free cultures on Matrigel in mTeSR1 medium than in the traditional 
MEF-cultures. Differentiation into the neural lineage was confirmed with cytometric analysis 
of polysialylated-neural cell adhesion molecule (PSA-NCAM) and immunocytochemistry for 
MAP-2. Moreover, one of the five lines cultured on Matrigel was also lost after 7 passages 
because of differentiation, as was also observed for this study.  
To maintain a pluripotent-cell morphology in feeder-free culture, the differentiated cells needed 
to be removed very carefully before passaging. Even when doing so, differentiated cells 
appeared to some degree at every passage. If not removed, their amount seemed to increase in 
time as also indicated by the loss of line E4G. Compared to the traditional culture methods 
including MEFs and knock-out serum replacement-based medium supplemented with β-FGF, 
the feeder-free method resulted in more spontaneous differentiation. In maintaining the 
pluripotency of the iPSCs, the traditional method can be considered better than the feeder-free 
conditions used in this study.  
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This study did not give answers to whether the neural differentiation arises from the matrix 
material or the medium. However, as the essential function of the MEF-cells is to provide the 
cytokine leukemia inhibitory factor (LIF), which directs PS-cell self-renewal through activation 
of the latent transcription factors STAT3 (Matsuda et al., 1999), the differentiation observed is 
more probably caused by components or by the absence of specific components in the medium 
than in the matrix. However, LIF alone is insufficient to prevent neural differentiation. A study 
by Ying et al. found that a N2B27 medium supplemented with LIF and BMP, however, could 
prevent neural differentiation of ES-cells in feeder-free culture on gelatin (Ying et al., 2003). 
Supplementing the culture media with these or other components and their ability to prevent 
neural differentiation into the neural lineage might reveal some answers to this question. Also 
other small molecules known to prevent neural differentiation might result in better 
maintenance in these culture conditions.  
Since both the medium and matrix material used in this study are derived of animal origin, the 
issue of xenogenicity is not prevented using these feeder-free conditions. Moreover, mTeSR1 
is not a fully defined medium. Since more differentiation is encountered in these conditions 
compared to the traditional method, the only true advantages compared to traditional MEF-
culturing observed in this study were the faster growth of iPSCs, less laborious passaging and 
depending on the use of the iPSCs, the absence of cells form another origin from the cultures. 
However, for in vitro and research purposes not requiring xenogenicity or fully defined 
conditions, the traditional MEF-culture method seems superior to the feeder-free method used 
in this study. 
6.4 Pluripotency gene expression 
The expression of pluripotency genes was studied at an early and later passage. Since the 
activation of the endogenic pluripotency genes in the iPSCs is thought to be a slow process 
(David and Polo, 2014), the aim was to study at which passage the pluripotency gene expression 
is upregulated. However, first RNA samples were obtained from passage 3, up to which point 
the expression had already reached levels similar to that observed at a later passage (Figure 
11).  Interestingly, a statistically significant decline from passage 3 to passage 9 was observed 
for NANOG (Figure 11). Nanog is a transcription factor regulated by Oct4 and Sox2 (Rodda 
et al., 2005). It has a role in maintaining the pluripotency through inhibition of the (BMP)-
signaling pathway (Suzuki et al., 2006). The expression of SOX2 was statistically significantly 
also decreased for patient 2 at the later passage (Figure 12B), which are in line with the 
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observed NANOG decline. However, these results were not observed for the other patients. 
Thus, the downregulation of NANOG could also be induced by OCT4, which was not studied 
in this thesis.  
Downregulation of NANOG has been shown to lead to differentiation in the ES-cells (Hyslop 
et al., 2005). However, all iPSC-lines were successfully maintained for almost ten passages 
even after this observed decline of NANOG expression, suggesting that although statistically 
significant, the decrease would not be sufficient to cause differentiation. Moreover, although 
statistically significant differences were observed, the fold changes in gene expression were 
small for all genes. This would indicate that the differences observed would more likely be 
caused by variation between individual iPSC-lines, which is frequently observed rather than 
meaningful differences in gene expression. In addition, also sample sizes especially between 
the different patients and patients at different passages were small. 
Although the activation of pluripotency genes is a time-consuming process, already at passage 
3 the pluripotency genes are expressed at levels comparable to a later passage. For obtaining 
more meaningful results, RNA from earlier passages could be used. Fold changes observed for 
all genes and lines were relatively small, indicating that even if statistical differences between 
lines could be observed, they may not be meaningful. Furthermore, as lines were reprogrammed 
by episomal plasmids that also express the studied pluripotency genes SOX2, C-MYC and 
KLF-4, and the absence of the plasmids was not confirmed at passage 3, it is impossible to 
know whether the gene expression is a result of only endogenous expression or a combination 
of endogenous+ plasmid expression, or only plasmid expression. However, NANOG was not 
included in the episomal plasmids, the expression of which can be assumed as completely 
endogenous. 
6.5 Cardiac differentiation 
Two iPSC-lines generated from the same patient with different methods were differentiated 
into cardiomyocytes by END-2 co-culture. The overall efficiencies were assessed by the 
number of beating areas appearing in the cultures and by the number of Troponin T-positive 
cells in these areas (Toivonen et al., 2013). While efficiencies as high as 25% have been 
reported (Graichen et al., 2008), the efficiencies observed in this study of 2.5% and 4.6% were 
fairly small even if a known differentiation enhancer AA and serum-free conditions were used 
(Passier et al., 2005; Takahashi et al., 2003). Better yields could be obtained by supplementing 
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the medium with p38 MAPK inhibitor, as originally reported in the study achieving 25% 
differentiation efficiency (Graichen et al., 2008). 
Since both lines chosen for comparison were maintained in same culture conditions and were 
used at the same passage, the differences between the efficiencies should reflect differences due 
to the reprogramming method. Assessed by both methods the sendai-viral line differentiated 
into cardiomyocytes more efficiently than the episomal-line with almost twice as high 
efficiency assessed by the number of beating areas (Table 5). These results would suggest that 
better differentiation efficiencies could be achieved with the use of sendai-virally 
reprogrammed iPSCs. However, since only two lines were compared, also variation observed 
between the different iPSCs-lines could explain the better reprogramming efficiency of line 
S2M. To achieve more significant results, more lines should be studied. However, since the 
differentiation efficiencies are usually overall very modest with the END2- method, a better 
way to increase the efficiency might be to choose another differentiation method, such as the 
2D-monolayer culture method, for which efficiencies as high as 95 % have been reported 
(Burridge et al., 2014). However, the END-2 co-culture method is the most robust, and easy 
method since differentiation is dependent on signals secreted by the END-2 cells, and not much 
information on the factors facilitating differentiation are needed. However, to create iPSC-
derived cardiomyocytes for possible future clinical use, a defined method with known and xeno-
free components should be used.  
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7. Conclusion 
One of the main aims of this study was to establish and characterise new iPSC-cell lines. Lines 
were generated with two different methods: either with sendai-viral reprogramming or episomal 
plasmid reprogramming with oriP/EBNA-1 plasmid system. In addition, two different culturing 
conditions were used: the traditional MEF-culturing and a feeder-free Geltrex®-culture 
method. While all studied patient cells were successfully reprogrammed into iPSC-lines 
according to the characterisations used in this study, the feeder-free lines elicited a much greater 
degree of differentiation in culture. Moreover, one of the two feeder-free iPSC-lines was 
completely lost due to differentiation. Since the feeder-free conditions used still contain 
xenogens and undefined components, as such it is ill-suited for regenerative medicine purposes 
or other applications requiring fully defined and xeno-free conditions. If aiming for research 
purposes not demanding these, the traditional MEF-culture method is considered superior to 
the feeder-free method. The few advantages achieved with feeder-free culturing were easier 
passaging and more rapid growth.  
The aim of gene expression studies was to assess at which point the pluripotency genes are 
activated during reprogramming. However, the first RNA samples were obtained only from p. 
3 at which point all the studied genes were already expressed at levels comparable to the later 
passage. Although a statistically significant difference for NANOG expression was observed 
(expression being lower at the later passage), the overall fold changes in gene expression were 
small. Since OCT4 is known to regulate NANOG, studying the expression of OCT4 could 
possibly have revealed more insight into the decreasing NANOG expression. 
Reprogramming efficiency was assessed for all episomally derived lines, cultured either in 
MEF- or feeder-free-cultures. Results of 5 patients revealed no difference in the differentiation 
efficiencies between culturing methods. Variability in the epigenetic or genetic states between 
the patients is more likely to cause the differences in reprogramming efficiency. 
In addition to reprogramming efficiency, also the cardiomyocyte differentiation efficiency was 
assessed by two methods for two lines derived from the same patient reprogrammed either 
sendai-virally or with the episomal plasmid -method. Results revealed more efficient 
differentiation of the sendai-virally derived iPSC-line. Thus, sendai-virally reprogrammed lines 
might differentiate more easily into cardiomyocytes. However, only two lines were chosen for 
62 
 
comparison and results from multiple lines would be needed to fully establish the superiority 
of the sendai-viral method for cardiac differentiation of iPSCs. Differentiation efficiencies 
observed in this study were low, both under 5%. Better efficiencies could be obtained by 
supplementing the medium with known enhancers or using another differentiation method such 
as a 2D monolayer culture method. 
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APPENDIX A 
 
The episomal vectors used in this study. A) The episomal vectors used were the Y4 combination. B) the episomal plasmid charts. (Modified from 
Okita et al., 2011)  
2 
 
APPENDIX B 
         
Immunocytochemistry for iPSC-lines E1.2, E2.3, S1M, S2M and S3M. Stained proteins included pluripotency markers Oct4, Sox2, SSEA4, TRA 
1-60 and TRA 1-81. Only merge-images for each line are shown.    
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APPENDIX C 
 
Karyotyping results for line E4G. The karyotype can be considered normal, if all probe values obtained for all chromosomes (except sex 
chromosomes) are 1 or close to one. The line E4G expressed a normal karyotype. (For more detailed description of the karyotyping analysis, see 
Lund et al. 2012) 
4 
 
APPENDIX D 
  
C-MYC SOX2 KLF4 NANOG GAPDH 
E1.1M p. 3 22,3 19,3 23,8 21,5 16,7 
E1.2M p. 3 22,1 20,1 24,2 20,8 16,9 
E1.3M p. 3 22,8 20,1 24,9 21,4 17,5 
E1.4M p. 3 21,7 20,0 23,9 21,2 17,1 
E2.1M p. 3 21,9 19,6 24,3 21,1 17,3 
E2.2M p.3 23,2 19,6 24,8 21,6 17,3 
E2.3M p. 3 22,9 20,5 24,9 21,6 17,8 
E2.4M p. 3 21,8 19,6 23,8 21,0 17,3 
E3.1M p. 3 22,7 20,6 25,5 21,4 17,5 
E3.2M p. 3 22,9 20,6 26,0 21,4 17,2 
E1.1M p. 9 22,0 19,3 23,7 21,4 16,4 
E1.2M p. 9 21,5 19,2 24,2 21,1 16,5 
E1.3M p. 9 22,2 19,3 24,8 21,3 16,6 
E1.4M p. 9 22,1 19,1 23,7 22,3 16,5 
E2.1M p. 9 21,0 19,3 23,9 20,9 16,6 
E2.2M p. 9 22,3 19,2 24,7 21,2 16,4 
E2.3M p. 9 21,1 19,5 23,5 20,7 16,5 
E3.1M p. 9 21,1 19,5 23,6 21,0 16,3 
E3.2M p. 9 21,4 19,8 23,5 21,3 16,6 
 
Ct-values determined using 7300 SDS Software (Applied Biosystems). Gene expression data for genes C-MYC, SOX2, KLF4 and GAPDH was 
obtained with a real-time-qPCR performed with the 7300 Real-time PCR system with Taqman chemistry using commercial probes. The values 
presented are means as each sample was prepared in triplicate. 
